|
|
|
8731 |
|
N/A |
|
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial Classification Code Number) |
|
(I.R.S. Employer
Identification Number) |
|
Jonathan M. Nathan, Adv. Meitar Law Offices
16 Abba Hillel Road
Ramat Gan, Israel 5251608
Tel: +972-3-610-3100 |
Mark S. Selinger, Esq. Gary Emmanuel,
Esq.
Greenberg
Traurig, LLP
One Vanderbilt Avenue New York, New York 10017-5404 Tel: (212) 801-9200 |
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
|
☒ |
Smaller reporting company |
|
|
|
|
Emerging growth company |
|
|
|
● |
the ability to maintain the listing of our ordinary shares and our warrants
on Nasdaq; |
|
|
|
|
|
|
● |
our future performance, including our projected timeline for regulatory approvals
of its product candidates; |
|
|
● |
our market opportunity; |
|
|
● |
our strategy, future operations, financial position, projected costs, prospects
and plans; |
|
|
● |
expectations regarding the time during which we will be an emerging growth
company under the JOBS Act; |
|
|
● |
our ability to retain or recruit officers, key employees and directors;
|
|
|
● |
the impact of the regulatory environment and complexities with compliance
related to such environment; |
|
|
● |
expectations regarding future partnerships or other relationships with third
parties; and |
|
|
● |
our future capital requirements and sources and uses of cash, including the
our ability to obtain additional capital in the future. |
|
● |
we are a development-stage company and have a limited operating history on
which to assess our business; |
|
● |
we have never generated any revenue from product sales and may never be profitable;
|
|
● |
we will need to raise substantial additional funding, which may not be available
on acceptable terms, or at all, and which will cause dilution to our shareholders; |
|
● |
the approach we are taking to discover and develop novel RNAi therapeutics
is unproven for oncology and may never lead to marketable products; |
|
● |
we do not have experience producing our product candidates at commercial
levels, currently have no marketing and sales organization, have an uncertain market receptiveness to our product candidates, and are
uncertain as to whether there will be insurance coverage and reimbursement for our potential products; |
|
● |
we may be unable to attract, develop and/or retain our key personnel or additional
employees required for our development and future success; |
|
● |
we may issue additional ordinary shares or other equity securities without your approval, including: (a)
up to $15,337,500 of ordinary shares issuable under the Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of August
15, 2024, by and between the Company and White Lion Capital, LLC (“White Lion”) (the “White Lion Purchase Agreement”
or “ELOC Agreement”), which established an equity line of credit for the Company; (b) ordinary shares underlying 659,999
outstanding warrants; and (c) ordinary shares underlying convertible promissory notes that the Company has issued to (i) Moringa’s
sponsor, Moringa Sponsor, LP, a Cayman Islands exempted limited partnership (the “Sponsor” or “Moringa Sponsor”),
in a principal amount of $3,433,000 (the “A&R Sponsor Promissory Note”), in amendment and restatement of all promissory
notes previously issued by Moringa to the Sponsor for funds borrowed between Moringa’s initial public offering and the completion
of the Business Combination, and (ii) EarlyBird Capital, Inc. (“EarlyBird”), which served as the representative of the underwriters
for Moringa’s initial public offering, in an amount of $1,250,000 (the “EarlyBird Convertible Note”), each of which
would dilute your ownership interest and may depress the market price of our ordinary shares; and |
|
● |
those additional factors described or incorporated by reference under the
heading “Risk Factors” below. |
|
|
Page |
| 1 | |
| 6 | |
| 42 | |
| 42 |
| 43 | |
| 44 | |
| 44 | |
| 44 | |
| 57 | |
| 80 | |
| 109 | |
| 115 | |
| 126 | |
| 129 | |
| 131 | |
| 135 | |
| 142 | |
| 149 | |
| 151 | |
| 151 | |
| 152 | |
|
F-1 |
|
● |
We are a development-stage company and have a limited operating history on
which to assess our business. The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and
may never lead to marketable products. |
|
● |
We have never generated any revenue from product sales and may never be profitable.
|
|
● |
We will need to raise substantial additional funding, which may not be available
on acceptable terms, or at all, and which will cause dilution to our shareholders. |
|
● |
Our independent registered public accounting firm’s report contains
an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.”. |
|
● |
The approach we are taking to discover and develop novel RNAi therapeutics
is unproven for oncology and may never lead to marketable products. |
|
● |
We are heavily dependent on the success of our product candidates, which
are in the early stages of preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive
regulatory approval, which is necessary before they can be commercialized. |
|
● |
The regulatory approval processes of the FDA and comparable foreign authorities
are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates,
our business will be substantially harmed. |
|
● |
Clinical drug development involves a lengthy and expensive process with an
uncertain outcome, and results of preclinical activity or earlier studies may not be predictive of future study results. |
|
● |
We may find it difficult to enroll patients in our clinical studies, which
could delay or prevent clinical studies of our product candidates. |
|
● |
Our product candidates and the administration of our product candidates may
cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile
of an approved label, or result in significant negative consequences following marketing approval, if any. |
|
● |
Even if we obtain regulatory approval for a product candidate, our products
will remain subject to regulatory scrutiny. |
|
● |
We are subject to a multitude of manufacturing risks, any of which could
substantially increase our costs and limit supply of our product candidates. |
|
● |
We rely on third parties to conduct our preclinical and clinical studies,
and to manufacture the raw materials and products that we use to create our product candidates and to supply us with the medical devices
used to administer such products, which entails regulatory and trade secrets-related risks. |
|
● |
We do not have experience producing our product candidates at commercial
levels, currently have no marketing and sales organization, have an uncertain market receptiveness to our product candidates, and is uncertain
as to whether there will be insurance coverage and reimbursement for our potential products. |
|
● |
We face intense competition and rapid technological change and the possibility
that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our
financial condition and our ability to successfully commercialize our product candidates. |
|
● |
If we are unable to obtain and maintain effective patent rights for our product
candidates or any future product candidates, we may not be able to compete effectively in our markets. |
|
● |
Third-party claims of intellectual property infringement may prevent or delay
our development and commercialization efforts. |
|
● |
We may be unable to attract, develop and/or retain our key personnel or additional
employees required for our development and future success. |
|
● |
Conditions in the Middle East and in Israel may harm our operations.
| |
| ● |
If we fail to maintain compliance with Nasdaq’s continued
listing requirements, our securities may be delisted from the Nasdaq Global Market. |
|
● |
A substantial number of our ordinary shares may be issued pursuant
to the conversion terms of the A&R Sponsor Promissory Note and the EarlyBird Convertible Note, which could cause the price of the
ordinary shares to decline | |
|
● |
The price of our ordinary shares and our warrants may be volatile.
| |
|
● |
A substantial number of our ordinary shares may be issued pursuant to the
White Lion Purchase Agreement and/or the conversion terms of the A&R Sponsor Promissory Note and the EarlyBird Convertible Note, which
could cause (i) substantial dilution and (ii) the market price of the ordinary shares to decline. | |
| ● |
We have no current plans to pay cash dividends on our ordinary shares for
the foreseeable future. | |
| ● |
Our reverse share split may negatively impact the market for our ordinary
shares. |
|
Ordinary shares currently outstanding |
8,414,615 ordinary shares. | |
|
Securities offered by the selling securityholders |
Up to 2,377,030 our ordinary shares, par value $0.0009 per share, consisting of (i) 2,221,523 ordinary
shares issuable upon the exercise of the New Warrants (as defined below), and (ii) 155,507 ordinary shares issuable upon the exercise
of the Placement Agent Warrants (as defined below). | |
|
Ordinary shares to be outstanding assuming exercise of the warrants |
10,791,645 ordinary shares. | |
|
Use of proceeds
|
We will not receive any proceeds from the sale of the ordinary shares issuable upon the exercise of the
warrants by the selling securityholders. All net proceeds from the sale of the ordinary shares issuable upon the exercise of the warrants
covered by this prospectus will go to the selling securityholders. However, we may receive the proceeds from any exercise of the warrants
and placement agent warrants if the holders do not exercise the warrants on a cashless basis. See the section of this prospectus titled
“Use of Proceeds.” |
|
Risk factors |
|
Before investing in our securities, you should carefully read
and consider the information set forth in “Risk Factors” beginning on page 6. |
|
|
|
|
|
Nasdaq ticker symbols |
|
New Silexion ordinary shares and New Silexion warrants are listed on Nasdaq under the symbols “SLXN”
and “SLXNW”, respectively. |
|
● |
continue and expand our research and preclinical and clinical development
of our product candidates; |
|
● |
initiate additional preclinical, toxicology, clinical, or other studies for
our product candidates; |
|
● |
continue to improve our quality standards and change or add additional manufacturers
or suppliers; |
|
● |
seek regulatory and marketing approvals for our product candidates that successfully
complete clinical studies; |
|
● |
establish a sales, marketing, and distribution infrastructure to commercialize
any products for which we may obtain marketing approval; |
|
● |
seek to identify, assess, acquire, license, and/or develop other product
candidates; |
|
● |
enter into license agreements; |
|
● |
seek to maintain, protect, and expand our intellectual property portfolio;
|
|
● |
seek to attract and retain skilled personnel; |
|
● |
create additional infrastructure to support our operations as a public company
and our product development and planned future commercialization efforts; and |
|
● |
experience any delays or encounter issues with any of the above, including
but not limited to failed studies, complex results, safety issues, or other regulatory challenges that require longer follow-up of
existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval. |
|
● |
completing research and preclinical and toxicology and clinical development
of our product candidates; |
|
● |
obtaining regulatory and marketing approvals for our product candidates,
if and when we complete clinical studies; |
|
● |
developing a sustainable and scalable in-house manufacturing process,
meeting all regulatory standards for approved product candidates, and in some instances, establishing and maintaining supply and manufacturing
relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical
development and the market demand for product candidates, if approved; |
|
● |
launching and commercializing product candidates, if and when we obtain regulatory
and marketing approval, either directly or with a collaborator or distributor; |
|
● |
exposing, educating and training physicians to use our products; |
|
● |
obtaining market acceptance of our product candidates as viable treatment
options; |
|
● |
addressing any competing technological and market developments; |
|
● |
identifying, assessing, acquiring and/or developing new product candidates;
|
|
● |
negotiating favorable terms in any collaboration, licensing, or other arrangements
into which we may enter; |
|
● |
maintaining, protecting, and expanding our portfolio of intellectual property
rights, including patents, trade secrets, and know-how; and |
|
● |
attracting, hiring, and retaining qualified personnel. |
|
● |
the scope, rate of progress, results and cost of our clinical studies, preclinical
testing, toxicology studies, and other related activities; |
|
● |
the cost of manufacturing clinical supplies, and establishing commercial
supplies of our product candidates and any future products; |
|
● |
the number and characteristics of product candidates that we pursue;
|
|
● |
the cost, timing, and outcomes of regulatory approvals; |
|
● |
the cost and timing of establishing sales, marketing, and distribution capabilities;
and |
|
● |
the terms and timing of any collaborative, licensing, and other arrangements
that we may establish. |
|
● |
the FDA or comparable foreign regulatory authorities may disagree with the
design or implementation of our clinical studies; |
|
● |
We may be unable to demonstrate to the FDA or comparable foreign regulatory
authorities that a product candidate’s benefit to risk ratio for our proposed indication is acceptable; |
|
● |
the population studied in the clinical program may not be sufficiently broad
or representative to assure safety in the full population for which we seek approval; |
|
● |
the FDA or comparable foreign regulatory authorities may disagree with our
interpretation of data from preclinical studies or clinical studies; |
|
● |
the data collected from clinical studies of our product candidates may not
be sufficient to support the submission of a new drug application (NDA) or a biologics license application (BLA) or other submission or
to obtain regulatory approval in the United States or elsewhere; |
|
● |
the FDA or comparable foreign regulatory authorities may fail to approve
the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract
for clinical and commercial supplies; and |
|
● |
the approval policies or regulations of the FDA or comparable foreign regulatory
authorities may significantly change in a manner rendering our clinical data insufficient for approval. |
|
● |
inability to generate sufficient preclinical, toxicology, or other in
vivo or in vitro data to support the initiation of human clinical studies;
|
|
● |
delays in reaching a consensus with regulatory agencies on study design;
|
|
● |
delays in reaching agreement on acceptable terms with prospective contract
research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly
among different CROs and clinical study sites; |
|
● |
delays in obtaining required Institutional Review Board (IRB) or Ethics Committee
approval at each clinical study site; |
|
● |
imposition of a clinical hold by regulatory agencies, after review of an
investigational new drug (IND) application, or equivalent application, or an inspection of our clinical study operations or study sites;
|
|
● |
difficulty collaborating with patient groups and investigators; |
|
● |
failure by our CROs, other third parties, or us to adhere to clinical study
requirements; |
|
● |
failure to perform in accordance with the FDA’s good clinical practices
requirements or applicable regulatory guidelines in other countries; |
|
● |
occurrence of serious adverse events associated with the product candidate
that are viewed to outweigh our potential benefits; |
|
● |
the cost of clinical studies of our drug candidates being greater than we
anticipate; |
|
● |
clinical studies of our drug candidates producing negative or inconclusive
results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug development
programs; and |
|
● |
failures associated with data interpretation, data management and data storage
of such studies. |
|
● |
regulatory authorities may withdraw approvals of such product; |
|
● |
regulatory authorities may require additional warnings on the label;
|
|
● |
We may be required to create a Risk Evaluation and Mitigation Strategy (REMS)
plan or similar plan in other jurisdictions, which could include a medication guide outlining the risks of such side effects for distribution
to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; |
|
● |
We could be sued and held liable for harm caused to patients; and |
|
● |
Our reputation may suffer. |
|
● |
issue warning letters; |
|
● |
impose civil or criminal penalties; |
|
● |
suspend or withdraw regulatory approval; |
|
● |
suspend any of our ongoing clinical studies; |
|
● |
refuse to approve pending applications or supplements
to approved applications submitted by Silexion; or |
|
● |
seize or detain products, or require a product recall.
|
|
● |
the process of manufacturing RNAi-drugs, drug substances, and RNAi-delivery
vehicles, such as our product candidates, is extremely susceptible to product loss due to contamination, equipment failure or improper
installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any
of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral,
or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are
made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;
and |
|
● |
the manufacturing facilities in which our product candidates are made could
be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors. |
|
● |
the timing of our receipt of any marketing and commercialization approvals;
|
|
● |
the terms of any approvals and the countries in which approvals are obtained;
|
|
● |
the safety and efficacy of our product candidates; |
|
● |
the prevalence and severity of any adverse side effects associated with our
product candidates; |
|
● |
limitations or warnings contained in any labeling approved by the FDA or
other regulatory authorities; |
|
● |
relative convenience and ease of administration of our product candidates;
|
|
● |
the willingness of patients to accept any new methods of administration;
|
|
● |
the success of our physician education programs; |
|
● |
the availability of adequate government and third-party payor reimbursement;
|
|
● |
the pricing of our products, particularly as compared to alternative treatments;
and |
|
● |
availability of alternative effective treatments for the disease indications
our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. |
|
● |
much greater financial, technical and human resources than we have at every
stage of the discovery, development, manufacture and commercialization of products; |
|
● |
more extensive experience in pre-clinical testing, conducting clinical
trials, obtaining regulatory approvals, and in manufacturing, marketing and selling pharmaceutical products; |
|
● |
product candidates that are based on previously tested or accepted technologies;
|
|
● |
products that have been approved or are in late stages of development; and
|
|
● |
collaborative arrangements in our target markets with leading companies and
research institutions. |
|
● |
the safety and effectiveness of our product; |
|
● |
the ease with which our product can be administered and the extent to which
patients accept relatively new routes of administration; |
|
● |
the timing and scope of regulatory approvals for our product; |
|
● |
the availability and cost of manufacturing, marketing and sales capabilities;
|
|
● |
price; |
|
● |
reimbursement coverage; and |
|
● |
patent position. |
|
● |
decreased demand for any approved product; |
|
● |
injury to our reputation; |
|
● |
withdrawal of clinical trial participants; |
|
● |
initiation of investigations by regulators; |
|
● |
costs to defend the related litigation; |
|
● |
a diversion of management’s time and our resources; |
|
● |
substantial monetary awards to trial participants or patients; |
|
● |
product recalls, withdrawals or labeling, marketing or promotional restrictions;
|
|
● |
exhaustion of any available insurance and our capital resources and potential
increase in our insurance premiums and/or retention amounts; and |
|
● |
the inability to commercialize any product candidate. |
|
● |
the potential disruption of our ongoing business; |
|
● |
the distraction of management away from the ongoing oversight of our existing
business activities; |
|
● |
incurring additional indebtedness; |
|
● |
the anticipated benefits and cost savings of those transactions not being
realized fully, or at all, or taking longer to realize than anticipated; |
|
● |
an increase in the scope and complexity of our operations; and |
|
● |
the loss or reduction of control over certain of our assets. |
|
The
sale of a substantial amount of our ordinary shares, including resale of the ordinary shares held by the Selling Securityholders in the
public market could adversely affect the prevailing market price of our ordinary shares. |
|
● |
actual or anticipated fluctuations in our financial condition or results
of operations; |
|
● |
variance in the projected timeline for regulatory approvals of our product
candidates from expectations of securities analysts; |
|
● |
changes in laws or regulations applicable to our business; |
|
● |
announcements by us or our competitors of significant business developments;
|
|
● |
significant data breaches, disruptions to or other incidents involving our
company; |
|
● |
conditions or developments affecting the biotechnology industry; |
|
● |
future sales of New Silexion ordinary shares by us or our shareholders, as
well as the anticipation of lock-up releases; |
|
● |
changes in senior management or key personnel; |
|
● |
the trading volume of our securities; |
|
● |
changes in the anticipated future size and growth rate of our markets;
|
|
● |
publication of research reports or news stories about us, our competitors
or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts; |
|
● |
general economic and market conditions; and |
|
● |
other events or factors, including those resulting from war, incidents of
terrorism, global pandemics or responses to those events. |
|
● |
limit our flexibility in planning the payment of expenditures that arise
in our clinical program and our business and operations generally; |
|
● |
increase our vulnerability to general adverse economic conditions that hinder
our ability to obtain equity financings; and |
|
● |
place us at a competitive disadvantage compared to our competitors.
|
|
● |
the interest rate payable under the EarlyBird Convertible Note could be increased,
and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding principal and interest to be due and payable;
and/or |
|
● |
we could be forced into bankruptcy or liquidation. |
|
TRANSACTIONS RELATED
TO OFFERING UNDER THIS PROSPECTUS |
|
MARKET AND INDUSTRY DATA
|
|
● |
Silexion’s shareholders holding approximately 61.55% of the outstanding
voting interests in New Silexion upon the Closing of the Transactions; |
|
● |
Silexion’s senior management comprise the senior management of New
Silexion; |
|
● |
the directors nominated by Silexion constitute the majority of the board
of directors of New Silexion (five out of seven of the initial directors); and |
|
● |
Silexion’s operations comprise the ongoing operations of New Silexion.
|
|
● |
the accompanying notes to the unaudited pro forma condensed combined financial
statements; |
|
● |
the historical unaudited financial statements of Moringa as of and for the
six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus; |
|
● |
the historical unaudited financial statements of New Silexion as of and for
the nine-months period ended September 30, 2024 and the related notes included elsewhere in this prospectus; |
|
● |
the historical audited financial statements of Moringa as of and for the
year ended December 31, 2023 and the related notes included elsewhere in this prospectus; |
|
● |
the historical audited financial statements of New Silexion as of and for
the year ended December 31, 2023 and the related notes included elsewhere in this prospectus; |
|
● |
the sections entitled “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” included in Moringa’s annual report on Form 10-K for the year
ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on April 1, 2024 and
August 13, 2024, respectively (the “Moringa 2023 Form 10-K” and “Moringa
Q2 Form 10-Q,” respectively), and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” included in this prospectus; |
|
● |
the other financial information relating to Moringa and New Silexion included
in this prospectus; and |
|
● |
factors detailed under the section entitled “Risk
Factors” in this prospectus. |
|
|
Historical |
Historical |
Actual Redemption |
||||||||||||||||
|
|
Moringa Acquisition
Corp (Period between January 1 and August
14, 2024) |
New Silexion |
Business Combination
Adjustments |
|
Pro Forma Statement of Operations |
||||||||||||||
|
Research and development expenses, net |
$ |
— |
$ |
4,944 |
A |
$ |
(2,424 |
) |
|
$ |
2,520 |
||||||||
|
|
|
||||||||||||||||||
|
General and administrative expenses |
551 |
5,727 |
A |
(3,438 |
) |
2,449 |
|||||||||||||
|
|
— |
— |
B |
75 |
|
||||||||||||||
|
|
— |
— |
C |
(466 |
) |
|
|||||||||||||
|
OPERATING LOSS |
551 |
10,671 |
(6,253 |
) |
4,969 |
||||||||||||||
|
Financial expenses (income), net |
(155 |
) |
4,092 |
D |
(134 |
) |
(740 |
) | |||||||||||
|
|
— |
— |
E |
(4,783 |
) |
|
|||||||||||||
|
|
F |
123 |
|
||||||||||||||||
|
|
G |
(337 |
) |
|
|||||||||||||||
|
|
H |
454 |
|
||||||||||||||||
|
Loss before income tax |
396 |
14,763 |
(10,930 |
) |
4,229 |
||||||||||||||
|
Tax on Income |
— |
9 |
— |
9 |
|||||||||||||||
|
LOSS FOR THE PERIOD |
$ |
396 |
$ |
14,772 |
$ |
(10,930 |
) |
|
$ |
4,238 |
|||||||||
|
|
|
||||||||||||||||||
|
Attributable to: |
|
||||||||||||||||||
|
Equity holders of the Company |
— |
14,696 |
I |
76 |
4,238 |
||||||||||||||
|
Non-controlling interests |
— |
76 |
I |
(76 |
) |
— |
|||||||||||||
|
|
|
||||||||||||||||||
|
PROFIT (LOSS) PER SHARE, BASIC AND DILUTED |
|
||||||||||||||||||
|
Ordinary share subject to possible redemption |
$ |
0.39 |
$ |
— |
$ |
(0.39 |
) |
|
$ |
— |
|||||||||
|
Non-redeemable ordinary shares |
$ |
(0.18 |
) |
$ |
(50.43 |
) |
$ |
46.85 |
|
$ |
(3.76 |
) | |||||||
|
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN
COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE |
|
||||||||||||||||||
|
Ordinary shares subject to possible redemption |
87,722 |
— |
(87,722 |
) |
|
||||||||||||||
|
Non-redeemable ordinary shares |
3,355,000 |
291,407 |
(2,519,042 |
) |
J |
1,127,365 |
|||||||||||||
|
|
Moringa Acquisition
Corp |
New Silexion |
Business Combination
Adjustments |
|
Pro Forma Statement
of Operations |
|||||||||||||||||
|
Research and development expenses, net |
$ |
— |
$ |
3,708 |
A |
$ |
2,424 |
|
$ |
6,132 |
||||||||||||
|
|
— |
— |
- |
|
||||||||||||||||||
|
General and administrative expenses |
1,122 |
973 |
A |
3,438 |
|
6,119 |
||||||||||||||||
|
|
— |
— |
- |
|
||||||||||||||||||
|
|
— |
— |
B |
120 |
|
|||||||||||||||||
|
|
— |
— |
C |
466 |
|
|||||||||||||||||
|
|
— |
— |
- |
|
||||||||||||||||||
|
OPERATING LOSS |
1,122 |
4,681 |
6,448 |
|
12,251 |
|||||||||||||||||
|
Financial expenses (income), net |
(1,385 |
) |
395 |
D
|
(86 |
) |
|
6,047 |
||||||||||||||
|
|
E
|
4,783 |
|
|||||||||||||||||||
|
|
F
|
1,364 |
|
|||||||||||||||||||
|
|
G
|
337 |
|
|||||||||||||||||||
|
|
H
|
639 |
|
|||||||||||||||||||
|
Loss before income tax |
(263 |
) |
5,076 |
13,485 |
|
18,298 |
||||||||||||||||
|
Tax on Income |
— |
32 |
— |
|
32 |
|||||||||||||||||
|
LOSS FOR THE PERIOD |
$ |
(263 |
) |
$ |
5,108 |
$ |
13,485 |
|
$ |
18,330 |
||||||||||||
|
|
|
|||||||||||||||||||||
|
Attributable to: |
|
|||||||||||||||||||||
|
Equity holders of the Company |
— |
4,942 |
I
|
166 |
|
18,330 |
||||||||||||||||
|
Non-controlling interests |
— |
166 |
I
|
(166 |
) |
|
— |
|||||||||||||||
|
|
|
|||||||||||||||||||||
|
PROFIT (LOSS) PER SHARE, BASIC AND DILUTED |
|
|||||||||||||||||||||
|
Ordinary share subject to possible redemption |
$ |
0.51 |
$ |
— |
$ |
(0.51 |
) |
|
$ |
— |
||||||||||||
|
Non-redeemable ordinary shares |
$ |
(0.34 |
) |
$ |
(44.23 |
) |
$ |
28.30 |
|
$ |
(16.27 |
) | ||||||||||
|
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
|
|||||||||||||||||||||
|
Ordinary shares subject to possible redemption |
2,774,850 |
— |
(2,774,850 |
) |
|
— |
||||||||||||||||
|
Non-redeemable ordinary shares |
3,355,000 |
111,726 |
(2,340,293 |
) |
J |
1,126,433 |
||||||||||||||||
|
● |
Moringa Sponsor forfeited for retirement 1,308,000 of the Moringa founders
shares held by it, while 1,567,000 of the Moringa founders shares were transferred to non-affiliated third-party investors (including
316,750 founders shares to certain security holders) as Backstop Shares (as defined in the Business Combination Agreement); |
|
● |
New Silexion issued to the Moringa Sponsor the A&R Sponsor Promissory
Note in an amount of $3,433,000, in replacement of all promissory notes that Moringa had issued to the Moringa Sponsor for amounts owed
by Moringa to the Moringa Sponsor prior to the Closing; |
|
● |
New Silexion, Moringa Sponsor, the investor in the PIPE financing
(described below) and certain additional shareholders of New Silexion entered into an Amended and Restated Registration Rights and Lock-Up
Agreement granting them registration rights with respect to the ordinary shares of New Silexion issued to them; and |
|
● |
Guangzhou Sino-Israel Bio-Industry Investment Fund I (“GIBF”),
a shareholder of Silexion, transferred its noncontrolling interest in Silexion’s Chinese subsidiary, Silenseed (China) Ltd., directly
to New Silexion, such that the subsidiary became a wholly-owned subsidiary of New Silexion, and was issued 203,971 ordinary shares of
New Silexion as consideration for that transfer (the “Chinese Subsidiary Transfer”)
(in addition to the 16,817 New Silexion ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it).
|
|
● |
the redemption of the 427,297 Moringa public shares described above;
|
|
● |
the separation of each former Moringa unit into one Moringa Class A ordinary
share and one-half of a Moringa warrant; |
|
● |
t1he Sponsor Founder Shares Forfeiture (as defined in the Business Combination Agreement) of 1,308,000
Moringa founders shares, and the transfer of the remaining 1,567,000 Moringa founders shares to third parties (including 316,750 Moringa
founders shares to certain securityholders) as Backstop Shares, which resulted in the issuance of 174,112 ordinary shares of New Silexion;
|
|
● |
the issuance of 9,747 New Silexion ordinary shares in exchange for 87,722
Moringa public shares that remained outstanding immediately prior to the Closing (following the redemptions described above); |
|
● |
the issuance of 42,223 New Silexion ordinary shares in exchange
for 380,000 Moringa private shares; |
|
● |
the issuance of 11,112 New Silexion ordinary shares to EarlyBird
in exchange for 100,000 Moringa representative shares; |
|
● |
the issuance by New Silexion to the Sponsor and/or its limited
partners to whom the Sponsor distributed such shares of the 153,592 Sponsor Investment Shares (as defined in the Business Combination
Agreement); |
|
● |
the issuance of 22,223 New Silexion ordinary shares to Greenstar, L.P. in
exchange for 200,000 Moringa shares that were purchased in the $2.0 million PIPE financing, as described above; |
|
● |
the issuance of 446,835 New Silexion ordinary shares as the
Silexion Merger Consideration (as defined in the Business Combination Agreement) to security holders of Silexion; |
|
● |
the issuance of 203,971 New Silexion ordinary shares to GIBF in respect of
the Chinese Subsidiary Transfer (in addition to 16,817 New Silexion ordinary shares issued to GIBF upon the accelerated vesting of RSUs
granted to it), as described above; and |
|
● |
the issuance of 4,370 New Silexion ordinary shares to a non-employee director
of New Silexion upon acceleration of vesting, and settlement, of an equivalent number of New Silexion RSUs granted to the director.
|
|
Equity Holders |
Shares |
Percentage of
Outstanding
Shares |
||||||
|
Moringa Public Shareholders(1) |
9,747 |
0.88 |
% | |||||
|
Silexion Shareholders(2) |
694,491 |
62.46 |
% | |||||
|
Moringa Sponsor Shares(3) |
187,798 |
16.89 |
% | |||||
|
Distributees of Sponsor Investment Shares |
5,000 |
0.45 |
% | |||||
|
PIPE investor |
22,223 |
2.00 |
% | |||||
|
Founders Shares/ Backstop Shares |
174,112 |
15.66 |
% | |||||
|
EarlyBird(3) |
14,127 |
1.27 |
% | |||||
|
Director receiving RSU grant upon Closing |
4,370 |
0.39 |
% | |||||
|
Total |
1,111,868 |
100 |
% | |||||
|
(1) |
Excludes 638,889 public warrants held by Moringa’s public
shareholders, which will be exercisable for New Silexion ordinary shares at an exercise price of $103.50 per share beginning 30 days after
the Closing of the Business Combination. |
|
(2) |
Includes all securities issuable to security holders of Silexion on a fully-diluted
basis, including New Silexion ordinary shares, New Silexion warrants, New Silexion options and New Silexion RSUs, and also includes 203,971
New Silexion ordinary shares issued directly to GIBF in respect of the Chinese Subsidiary Transfer, as well as 16,817 New Silexion ordinary
shares issued to GIBF upon the accelerated vesting of RSUs granted to it. |
|
(3) |
Excludes 21,112 private warrants held, in the aggregate, by
the Moringa Sponsor and EarlyBird, which will be exercisable for New Silexion ordinary shares at an exercise price of $103.50 per share
beginning 30 days after the Closing of the Business Combination. |
|
|
|
Moringa Acquisition Corp (Period between January 1 and August 14,
2024) (Historical) |
|
|
|
|
|
|
| |||||||
|
For the nine-months period ended September 30, 2024 |
|
Class A subject to Possible Redemption |
|
|
Non- redeemable Class A and Class B |
|
|
New Silexion (Historical) |
|
|
Pro Forma Combined (Actual Redemption) |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
Weighted average shares outstanding – basic and diluted |
|
|
87,722 |
|
|
|
3,355,000 |
|
|
|
291,407 |
|
|
|
1,127,365 |
|
|
Net profit (loss) per share – basic |
|
$ |
0.39 |
|
|
$ |
(0.18 |
) |
|
$ |
(50.43 |
) |
|
$ |
(3.76 |
) |
|
|
|
Moringa Acquisition Corp (Historical) |
|
|
|
|
|
| ||||||||
|
For the year ended December 31, 2023 |
|
Class A subject to Possible Redemption |
|
|
Non- redeemable Class A and Class B |
|
|
New Silexion (Historical) |
|
|
Pro Forma
Combined (Actual Redemption) |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
Weighted average shares outstanding – basic and diluted |
|
|
2,774,850 |
|
|
|
3,355,000 |
|
|
|
111,726 |
|
|
|
1,126,433 |
|
|
Net profit (loss) per share – basic |
|
$ |
0.51 |
|
|
$ |
(0.34 |
) |
|
$ |
(44.23 |
) |
|
$ |
(16.27 |
) |
|
● |
apply for Orphan Drug Designation in both the U.S. and EU for its SIL-204B
product; |
|
● |
initiate a clinical trial powered for statistical significance with respect
to SIL-204B; |
|
● |
initiate toxicological studies with respect to SIL-204B; |
|
● |
seek marketing approvals for SIL-204B in various territories; |
|
● |
maintain, expand and protect our intellectual property portfolio; |
|
● |
hire additional operational, clinical, quality control and scientific personnel;
|
|
● |
add operational, financial and management information systems and personnel,
including personnel to support our product development, any future commercialization efforts and our prospective transition to a public
company; and |
|
● |
invest in research and development and regulatory approval efforts in order
to utilize our technology as a platform focused on the silencing of the KRAS oncogene using RNA-interference therapeutics. |
|
|
● |
Sponsor/Silexion Lock-Up Period: (A) 50% of the Sponsor Investment
Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders who are
party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier of (i) six (6) months after
the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation,
share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Silexion’s
shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of the Sponsor
Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders
party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6)
months after the date of the consummation of the Business Combination, (y) the date on which New Silexion consummates a liquidation, merger,
amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Silexion’s
shareholders having the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the last
reported sale price of New Silexion’s ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends,
rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period.
|
|
|
● |
Private Shares and Private Warrants Lock-Up Period: The lock-up
period on all New Silexion ordinary shares issued pursuant to the Business Combination in exchange for private placement shares and private
placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa’s initial public offering will
remain (as provided in the documentation for Moringa’s initial public offering) 30 days after the Closing. |
|
|
● |
Representative Shares Lock-Up
Period. The lock-up period on all representative shares that are held by EarlyBird will remain (as provided in the documentation
for Moringa’s initial public offering) three months after the Closing. |
|
|
● |
Note Shares and PIPE Shares Lock-Up
Period. Note Shares (as defined under “Amended and Restated Sponsor Promissory Note”
below) issued to the Sponsor upon conversion of amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the PIPE
Investor are not subject to any lock-up periods following the Closing. |
|
Nine-month period ended September 30, |
||||||||
| 2024 |
2023 |
|||||||
|
(U.S. dollars, in thousands) |
||||||||
|
Operating expenses: |
||||||||
|
Research and development, net |
$ |
4,944 |
$ |
2,451 |
||||
|
General and administrative |
5,727 |
502 |
||||||
|
Total operating expenses |
10,671 |
2,953 |
||||||
|
Operating loss |
10,671 |
2,953 |
||||||
|
Financial expenses, net |
4,092 |
449 |
||||||
|
Loss before income tax |
14,763 |
3,402 |
||||||
|
Income tax |
9 |
26 |
||||||
|
Net loss for the nine-month period |
$ |
14,772 |
$ |
3,428 |
||||
|
|
Nine-month period ended September 30, |
|||||||
|
|
2024 |
2023 |
||||||
|
|
(U.S. dollars, in thousands) |
|||||||
|
Payroll and related expenses |
$ |
928 |
$ |
729 |
||||
|
Share-based compensation expenses |
2,424 |
57 |
||||||
|
Subcontractors and consultants |
1,425 |
1,444 |
||||||
|
Materials |
3 |
16 |
||||||
|
Rent and maintenance |
106 |
124 |
||||||
|
Travel expenses |
13 |
27 |
||||||
|
Other |
45 |
54 |
||||||
|
Total research and development expenses |
$ |
4,944 |
$ |
2,451 |
||||
|
|
|
Nine-month periods ended September 30, |
| |||||
|
|
|
2024 |
|
|
2023 |
| ||
|
|
|
(U.S. dollars, in thousands) |
| |||||
|
Payroll and related expenses |
|
$ |
856 |
|
|
$ |
190 |
|
|
Share-based compensation expenses |
|
|
3,438 |
|
|
|
39 |
|
|
Professional services |
|
|
1,053 |
|
|
|
79 |
|
|
Depreciation |
|
|
37 |
|
|
|
39 |
|
|
Rent and maintenance |
|
|
90 |
|
|
|
67 |
|
|
Patent registration |
|
|
25 |
|
|
|
18 |
|
|
Travel expenses |
|
|
72 |
|
|
|
31 |
|
|
Other |
|
|
156 |
|
|
|
39 |
|
|
Total general and administrative expenses |
|
$ |
5,727 |
|
|
$ |
502 |
|
|
|
Three-month period ended September 30, |
|||||||
|
|
2024 |
2023 |
||||||
|
Operating expenses: |
(U.S. dollars, in thousands) |
|||||||
|
Research and development, net |
$ |
3,217 |
$ |
535 |
||||
|
General and administrative |
4,819 |
196 |
||||||
|
Total operating expenses |
8,036 |
731 |
||||||
|
Operating loss |
8,036 |
731 |
||||||
|
Financial expenses, net |
3,822 |
72 |
||||||
|
Loss before income tax |
11,858 |
803 |
||||||
|
Income tax |
2 |
6 |
||||||
|
Net loss for the three-month period |
$ |
11,860 |
$ |
809 |
||||
|
|
Three-month period ended September 30, |
|||||||
|
|
2024 |
2023 |
||||||
|
|
(U.S. dollars, in thousands) |
|||||||
|
Payroll and related expenses |
$ |
453 |
$ |
198 |
||||
|
Share-based compensation expenses |
2,385 |
19 |
||||||
|
Subcontractors and consultants |
297 |
236 |
||||||
|
Materials |
- |
- |
||||||
|
Rent and maintenance |
57 |
46 |
||||||
|
Travel expenses |
- |
- |
||||||
|
Other |
25 |
36 |
||||||
|
Total research and development expenses |
$ |
3,217 |
$ |
535 |
||||
|
Three-month period ended September 30, |
||||||||
| 2024 |
2023 |
|||||||
|
|
(U.S. dollars, in thousands) |
|||||||
|
Payroll and related expenses |
$ |
575 |
$ |
71 |
||||
|
Share-based compensation expenses |
3,413 |
13 |
||||||
|
Professional services |
605 |
51 |
||||||
|
Depreciation |
22 |
10 |
||||||
|
Rent and maintenance |
18 |
25 |
||||||
|
Patent registration |
- |
2 |
||||||
|
Travel expenses |
56 |
15 |
||||||
|
Other |
130 |
9 |
||||||
|
Total general and administrative expenses |
$ |
4,819 |
$ |
196 |
||||
|
Comparison of Years
ended December 31, 2023 and 2022 |
|
Years ended December 31, |
||||||||
|
2023 |
2022 |
|||||||
|
Operating expenses: |
||||||||
|
Research and development, net |
$ |
3,708 |
$ |
3,226 |
||||
|
General and administrative |
973 |
634 |
||||||
|
Total operating expenses |
4,681 |
3,860 |
||||||
|
Operating loss |
4,681 |
3,860 |
||||||
|
Financial expenses (income), net |
395 |
(396 |
) | |||||
|
Loss before income tax |
5,076 |
3,464 |
||||||
|
Income tax |
32 |
24 |
||||||
|
Net loss for the year |
$ |
5,108 |
$ |
3,488 |
||||
|
Research and Development Expenses
|
|
Years ended December 31, |
||||||||
| 2023 | 2022 | |||||||
|
Payroll and related expenses |
$ |
973 |
$ |
1,192 |
||||
|
Subcontractors and consultants |
2,467 |
1,595 |
||||||
|
Materials |
13 |
191 |
||||||
|
Rent and maintenance |
160 |
175 |
||||||
|
Travel expenses |
37 |
42 |
||||||
|
Other |
58 |
31 |
||||||
|
Total research and development expenses |
$ |
3,708 |
$ |
3,226 |
||||
|
Years ended December 31, |
||||||||
|
2023 |
2022 |
|||||||
|
Payroll and related expenses |
$ |
356 |
$ |
219 |
||||
|
Professional Services |
386 |
197 |
||||||
|
Depreciation |
45 |
57 |
||||||
|
Rent and maintenance |
86 |
71 |
||||||
|
Patent registration |
22 |
32 |
||||||
|
Travel expenses |
31 |
— |
||||||
|
Other |
47 |
58 |
||||||
|
Total general and administrative expenses |
$ |
973 |
$ |
634 |
||||
|
Financial expenses, net |
|
Net loss |
|
|
Nine-month period ended September 30, |
|||||||
|
|
2024 |
2023 |
||||||
|
(U.S. dollars, in thousands) |
||||||||
|
Cash and cash equivalents and restricted cash at beginning
of the period |
$ |
4,645 |
$ |
8,309 |
||||
|
Net cash used in operating activities |
(5,470 |
) |
(3,272 |
) | ||||
|
Net cash provided by (used in) investing activities
|
(22 |
) |
577 |
|||||
|
Net cash provided by financing activities |
2,920 |
522 |
||||||
|
Net decrease in cash and cash equivalents and restricted
cash |
$ |
(2,572 |
) |
$ |
(2,173 |
) | ||
|
Translation adjustments on cash and cash equivalents and
restricted cash |
(50 |
) |
(324 |
) | ||||
|
Cash and cash equivalents and restricted cash at end of
the period |
$ |
2,023 |
$ |
5,812 |
||||
|
|
Three-month period ended September 30, |
|||||||
|
|
2024 |
2023 |
||||||
|
(U.S. dollars, in thousands) |
||||||||
|
Cash and cash equivalents and restricted cash at the beginning
of the period |
$ |
1,747 |
$ |
6,491 |
||||
|
Net cash used in operating activities |
(2,653 |
) |
(685 |
) | ||||
|
Net cash provided by (used in) investing activities
|
(16 |
) |
72 |
|||||
|
Net cash provided by financing activities |
2,920 |
- |
||||||
|
Net decrease in cash and cash equivalents and restricted
cash |
$ |
251 |
$ |
(613 |
) | |||
|
Translation adjustments on cash and cash equivalents and
restricted cash |
25 |
(66 |
) | |||||
|
Cash and cash equivalents and restricted cash at the end
of the period |
$ |
2,023 |
$ |
5,812 |
||||
|
|
Year ended December 31, |
|||||||
|
|
2023 |
2022 |
||||||
|
Cash and cash equivalents and restricted cash at beginning
of the period |
$ |
8,309 |
$ |
10,083 |
||||
|
Net cash used in operating activities |
(4,529 |
) |
(3,335 |
) | ||||
|
Net cash provided by (used in) investing activities
|
573 |
(524 |
) | |||||
|
Net cash provided by financing activities |
522 |
2,752 |
||||||
|
Net decrease in cash and cash equivalents and restricted
cash |
$ |
(3,434 |
) |
$ |
(1,107 |
) | ||
|
Translation adjustments on cash and cash equivalents and
restricted cash |
(230 |
) |
(667 |
) | ||||
|
Cash and cash equivalents and restricted cash at the end
of the period |
$ |
4,645 |
$ |
8,309 |
||||
|
● |
Material cost. |
|
● |
Regulatory pathway; and |
|
● |
Human clinical trial costs. |
| ● |
significant dilution to the equity interests of our current shareholders; |
| ● |
a deemed change of control of our company due to the issuance of a substantial number of ordinary
shares, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in a
change in the officers and directors of our company relative to our current officers and directors, to the extent any shareholders build
up significant beneficial ownership from ordinary shares issued pursuant to the ELOC; |
| ● |
may have the effect of delaying or preventing a change of control of our company by diluting
the share ownership or voting rights of a person seeking to obtain control; and |
| ● |
may adversely affect prevailing market prices for our ordinary shares or
warrants. |
|
● |
History of transactions in our preferred shares;
|
|
● |
Probability of an IPO scenario (including de SPAC transaction);
|
|
● |
Probability of other liquidation events; |
|
|
|
| |
|
● |
Expected time to liquidation; and |
|
● |
Expected return on equity. |
|
KRAS
G12x Mutation |
|
Cohort 1
Arm 2 (Control) |
|
Cohort 1
Arm 1 (Treatment) |
|
Cohort 1
% Arm 1 Tx |
|
Cohort 2 (Treatment) |
|
All Treated % |
|
R |
|
5/10 |
|
1/12 |
|
8 |
|
2/9 |
|
26 (8/31) |
|
D |
|
2/10 |
|
3/12 |
|
25 |
|
2/9 |
|
23 (7/31) |
|
V |
|
3/10 |
|
8/12 |
|
67 |
|
5/9 |
|
52 (16/31) |
|
● |
Advancing the clinical
development of SIL-204B for the treatment of LAPC. Our Phase 2
trial with our first-generation siRNA product, Loder in LAPC patients acts as a validation of approach and foundation for our continued
development efforts. As further described in “Future Development Plans”, Silexion plans to initiate toxicology studies of
SIL-204B in 2025 followed by the regulatory submission in late 2025 to initiate a Phase 2/3 trial of SIL-204B powered for statistical
significance. At this time, Silexion is focused on the further development of the core siRNA technology underlying the Loder and SIL-204B as
well as the clinical development of SIL-204B as the most optimized version of the technology. |
|
● |
Leveraging our platform
to other oncological indications harboring the KRASG12D/V mutation.
|
|
● |
Advancing SIL-204B to
commercialization. We have assembled a world class clinical advisory
board for better understanding the market in the U.S. and EU. |
|
● |
Forming strategic alliances
and collaborating with partners to augment our capabilities. We
may pursue strategic alliances with other biopharmaceutical companies with well-established presences in the specialties we aim to
target for our indications. This may include co-marketing, co-promotion, and co-development relationships, or a partnership with
a diagnostics company to help improve availability of rapid testing. We also intend to explore options to work with partners to augment
the study and treatment of patients and the impact of our product candidates, including medical professionals, healthcare professional
networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies. |
|
● |
completion of extensive preclinical laboratory tests and preclinical animal
studies, all performed in accordance with the GLP regulations; |
|
● |
submission to the FDA of an investigational new drug application, or IND,
Clinical Trial Application (CTA) for Europe which must become effective or approved before human clinical studies may begin and must be
updated on a regular basis; |
|
● |
approval by an independent institutional review board, or IRB, or ethics
committee representing each clinical site before each clinical study may be initiated; |
|
● |
performance of adequate and well-controlled human clinical studies to
establish the safety and efficacy of the product candidate for each proposed indication; |
|
● |
preparation of and submission to the FDA of a new drug application, or NDA,
or biologics license application, or BLA, or for Europe a Marketing Authorization Application (MAA) after completion of all pivotal clinical
studies; |
|
● |
potential review of the product application by an FDA advisory committee,
where appropriate and if applicable. In the EU, the Committee for Medicinal Products for Human Use (CHMP) issues a scientific opinion
to the European Commission which issues the marketing authorization; |
|
● |
a determination by the FDA within 60 days of its receipt of an NDA or
BLA to file the application for review; |
|
● |
satisfactory completion of an FDA pre-approval inspection of the manufacturing
facilities where the proposed product drug substance is produced to assess compliance with cGMP; and |
|
● |
FDA review and approval of an NDA or BLA or marketing authorization in the
European Union (EU) in all European Union Member States plus Norway, Iceland and Liechtenstein, prior to any commercial marketing or sale
of the drug in the United States. Note that if the centralized procedure is used, which is mandatory for all new anticancer products,
a marketing authorization is issued centrally by the EU commission, which is valid immediately in all member states of the EEA (EU plus
Iceland, Norway, and Liechtenstein). |
|
● |
obtaining regulatory approval to commence a study; |
|
● |
reaching agreement with third-party clinical trial sites and their subsequent
performance in conducting accurate and reliable studies on a timely basis; |
|
● |
obtaining institutional review board approval or an Ethics Committee approval
to conduct a study at a prospective site; |
|
● |
recruiting patients to participate in a study; and |
|
● |
supply of the drug. |
|
● |
Phase 1. The
drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution
and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently
toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. |
|
● |
Phase 2. This
phase involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. |
|
● |
Phase 3. This
phase involves trials undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at
geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and
provide an adequate basis for product labeling. |
|
● |
Phase 4. In
some cases, the FDA or the EMA may condition approval of an NDA or BLA or MAA for a product candidate on the Sponsor’s agreement
to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after
approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.
|
|
● |
restrictions on the marketing or manufacturing of the product, complete withdrawal
of the product from the market or product recalls; |
|
● |
fines, warning letters or holds on post-approval clinical studies;
|
|
● |
refusal of the FDA to approve pending NDAs or supplements to approved NDAs,
or suspension or revocation of product license approvals; |
|
● |
injunctions or the imposition of civil or criminal penalties; or |
|
● |
product seizure or detention, or refusal to permit the import or export of
products. |
|
● |
the required patent information has not been filed; |
|
● |
the listed patent has expired; |
|
● |
the listed patent has not expired, but will expire on a particular date and
approval is sought after patent expiration; or |
|
● |
the listed patent is invalid, unenforceable or will not be infringed by the
new product. |
|
● |
Decentralized procedure. Using
the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal
products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized
procedure. |
|
● |
Mutual recognition procedure. In
the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures
of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby
the countries concerned agree to recognize the validity of the original, national marketing authorization. |
|
● |
the federal Anti-Kickback Statute, which prohibits, among other things,
persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in
return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare
and Medicaid programs; |
|
● |
federal civil and criminal false claims laws and civil monetary penalty laws,
which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment
from Medicare, Medicaid, or other third-party payers that are false or fraudulent; |
|
● |
the federal Health Insurance Portability and Accountability Act of 1996,
or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making
false statements relating to healthcare matters; |
|
● |
the federal transparency laws, including the federal Physician Payment Sunshine
Act, that requires drug manufacturers to disclose payments and other transfers of value provided to physicians and teaching hospitals;
|
|
● |
HIPAA, as amended by HITECH and its implementing regulations, which imposes
certain requirements relating to the privacy, security and transmission of individually identifiable health information; and |
|
● |
state law equivalents of each of the above federal laws, such as anti-kickback and
false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state
laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant
ways and may not have the same effect, thus complicating compliance efforts. |
|
Name |
|
Age |
|
Position(s) |
|
Directors |
|
|
|
|
|
Ilan Hadar |
|
55 |
|
Chairman and Chief Executive Officer |
|
Dror J. Abramov |
|
63 |
|
Director |
|
Ruth Alon |
|
72 |
|
Director |
|
Ilan Levin |
|
58 |
|
Director |
|
Avner Lushi |
|
57 |
|
Director |
|
Shlomo Noy |
|
71 |
|
Director |
|
Amnon Peled |
65 |
Director | ||
|
Executive Officers (who are not also directors)
|
|
|
|
|
|
Dr. Mitchell Shirvan |
|
70 |
|
Chief Scientific and Development Officer |
|
Mirit Horenshtein Hadar, CPA |
|
40 |
|
EVP of Finance Affairs, Chief Financial Officer and Secretary |
|
● |
helping the New Silexion Board oversee our corporate accounting and financial
reporting processes; |
|
● |
managing the selection, engagement, qualifications, independence, and performance
of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; |
|
● |
reviewing and discussing the scope and results of the audit with the independent
registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating
results; |
|
● |
obtaining and reviewing a report by the independent registered public accounting
firm at least annually that describes our internal quality control procedures, any material issues with such procedures and any steps
taken to deal with such issues when required by applicable law; |
|
● |
establishing procedures for employees to submit concerns anonymously about
questionable accounting or audit matters; |
|
● |
overseeing our policies on risk assessment and risk management; |
|
● |
overseeing compliance with our code of business conduct and ethics;
|
|
● |
reviewing related person transactions; and |
|
● |
approving or, as required, pre-approving audit and permissible non-audit services
to be performed by the independent registered public accounting firm. |
|
● |
reviewing, approving and determining, or making recommendations to the New
Silexion Board regarding the compensation of our chief executive officer, other executive officers and senior management; |
|
● |
reviewing, evaluating and recommending to the New Silexion Board succession
plans for our executive officers; |
|
● |
reviewing and recommending to the New Silexion Board the compensation paid
to our non-employee directors; |
|
● |
administering our equity incentive plans and other benefit programs;
|
|
● |
reviewing, adopting, amending and terminating incentive compensation and
equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections and any other compensatory arrangements
for our executive officers and other senior management; and |
|
● |
reviewing and establishing general policies relating to compensation and
benefits of our employees, including our overall compensation philosophy. |
|
● |
identifying and evaluating candidates, including the nomination of incumbent
directors for reelection and nominees recommended by shareholders, to serve on the New Silexion Board; |
|
● |
considering and making recommendations to the New Silexion Board regarding
the composition and chairmanship of the committees of the New Silexion Board; |
|
● |
instituting plans or programs for the continuing education of the New Silexion
Board and the orientation of new directors; |
|
● |
developing and making recommendations to the New Silexion Board regarding
corporate governance guidelines and matters; |
|
● |
overseeing our corporate governance practices; |
|
● |
overseeing periodic evaluations of the New Silexion Board’s performance,
including committees of the New Silexion Board; and |
|
● |
contributing to succession planning. |
|
Name and Principal Position |
Year |
Base Gross
Salary ($)(1) |
Stock Awards ($) |
All Other
Compensation ($)(1)(2) |
Total
($)(1) |
|||||||||||||
|
Ilan Hadar Chief Executive Officer (formerly Managing Director of Silexion)(3) |
2024 |
240,560 |
1,192,785 |
107,283 |
1,540,628 |
|||||||||||||
|
2023 |
182,976 |
- |
70,638 |
253,614 |
||||||||||||||
|
Mirit Horenshtein Hadar Chief Financial Officer (formerly EVP Finance of Silexion)(4) |
2024 |
233,532 |
447,291 |
89,267 |
770,090 |
|||||||||||||
|
2023 |
26,238 |
- |
- |
26,238 |
||||||||||||||
|
Dr. Mitchell Shirvan
Chief Scientific and Development Officer(5) |
2024 |
190,286 |
1,043,699 |
67,505 |
1,301,490 |
|||||||||||||
|
2023 |
156,140 |
- |
50,660 |
206,800 |
||||||||||||||
|
(1) |
Amounts reported for the named executive officer and paid in New Israeli Shekels are converted from New
Israeli Shekels to U.S. dollars using the 2024 and 2023 (as applicable) average exchange rates as published by Bank of Israel of
3.699 and 3.689 New Israeli Shekels, respectively, to 1 U.S. Dollar. |
|
(2) |
The amounts in this column include payments for a leased car or car maintenance, contributions to a pension
fund, compensation fund, and continuing education fund, or payments in lieu of a continuing education fund. |
|
(3) |
This was for a part-time (75%) position prior to, and a full-time position following, completion of
the Business Combination. |
|
(4) |
For 2023, Ms. Horenshtein Hadar’s compensation was for a period of 4.5 months during which she
served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity. |
|
(5) |
This was for a part-time (80%) position prior to, and a full-time position following, completion of
the Business Combination. |
|
Option awards |
||||||||||||||||||||
|
Name |
Number of securities underlying unexercised options (#) exercisable |
Number of securities underlying unexercised options (#) unexercisable |
Equity incentive plan awards: Number of securities underlying unexercised unearned options (#) |
Option exercise price ($) |
Option expiration date |
|||||||||||||||
|
Ilan Hadar Chief Executive Officer (formerly Managing Director of Silexion |
14,339 |
- | - |
60.51 |
24/03/2032 |
|||||||||||||||
|
Mirit Horenshtein Hadar Chief Financial Officer (formerly EVP Finance of Silexion |
-- |
- |
- |
- |
- |
|||||||||||||||
|
Dr. Mitchell Shirvan
Chief Scientific and Development Officer( |
7,170 |
- | - |
60.51 |
07/06/2032 |
|||||||||||||||
|
Name |
Fees earned or paid in cash ($) |
Stock awards ($) |
Option awards ($) |
All other compensation ($) |
Total ($) |
|||||||||||||||
|
Ilan Hadar |
See Summary Compensation Table above |
See Summary Compensation Table above |
See Summary Compensation Table above |
See Summary Compensation Table above |
See Summary Compensation Table above |
|||||||||||||||
|
Dror Abramov |
- |
313,800 |
- |
- |
313,800 |
|||||||||||||||
|
Ruth Alon |
- |
- |
- |
- |
- |
|||||||||||||||
|
Ilan Levin |
- |
- |
- |
45,000 |
45,000 |
|||||||||||||||
|
Avner Lushi |
- |
313,800 |
- |
- |
313,800 |
|||||||||||||||
|
Shlomo Noy |
- |
313,800 |
- |
- |
313,800 |
|||||||||||||||
|
Amnon Peled |
- |
- |
- |
- |
- |
|||||||||||||||
|
Ilan Shiloah (former director)
|
- |
313,800 |
- |
- |
313,800 |
|||||||||||||||
|
(a) |
entitle a grantee to exercise an award, or to otherwise provide for the acceleration
of such award’s vesting schedule, as to all or part of its underlying shares, including with respect to awards that would not otherwise
be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the cancellation of all unexercised
awards upon or immediately prior to the closing of a transaction or as of such other date (the “Cut-Off Date”),
and/or the termination of all awards (whether vested but un-exercised or un-vested) as of the relevant Cut-Off Date, as of which
they shall no longer be exercisable by the applicable grantees; and/or |
|
(b) |
provide for the cancellation of outstanding awards at or immediately prior
to the closing of a transaction, and payment to the applicable grantee of a consideration determined by the Administrator to be fair in
the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value of
each underlying share of any such award’s vested portion as reflected by the terms of such transaction, and the exercise price of
each such underlying share, and subject to such terms and conditions as determined by the Administrator. |
|
|
● |
The Share Pool will be reduced by one share for each share made subject to
an award granted under the 2024 Plan; |
|
|
|
|
|
|
● |
The Share Pool will be increased by the number of unissued shares underlying
or used as a reference measure for any award or portion of an award granted under the 2024 Plan that is cancelled, forfeited, expired,
terminated unearned or settled in cash, in any such case without the issuance of shares; |
|
● |
The Share Pool will be increased by the number of shares that are forfeited
back or surrendered for no consideration to us after issuance due to a failure to meet an award contingency or condition with respect
to any award or portion of an award granted under the 2024 Plan; |
|
● |
The Share Pool shall be increased, on the exercise date, by the number of
shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of any award
granted under the 2024 Plan; and |
|
● |
The Share Pool shall be increased, on the relevant date, by the number of
shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding obligation
that arises in connection with any award granted under the 2024 Plan. |
|
|
● |
the aggregate number and kind of shares or other securities that may be granted
to eligible individuals under the 2024 Plan; |
|
|
● |
the maximum number of shares or other securities that may be issued with
respect to incentive share options granted under the 2024 Plan; |
|
|
● |
the number of shares or other securities covered by each outstanding award
and the exercise price, base price or other price per share, if any, and other relevant terms of each outstanding award; and |
|
|
● |
all other numerical limitations relating to awards, whether contained in
the 2024 Plan or in award agreements. |
|
● |
the amounts involved exceeded or will exceed $120,000; and |
|
● |
any of our directors, executive officers or holders of more than 5% of our
share capital, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have
a direct or indirect material interest. |
|
● |
Sponsor Investment Shares and securities held by former Silexion shareholders:
(A) 50% of the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former
Silexion shareholders who are party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier
of (i) six (6) months after the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation,
merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all
of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of
the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the our securities held by the former Silexion shareholders
party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6)
months after the date of the consummation of the Business Combination, (y) the date on which we consummate a liquidation, merger, amalgamation,
share exchange, reorganization, or other similar transaction after the Business Combination that results in all of our shareholders having
the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the closing price of our
ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations,
recapitalizations and the like) for any 20 trading days within any 30-trading day period. |
|
● |
Private Shares and Private Warrants:
The lock-up period on all New Silexion ordinary shares issued pursuant to the SPAC Merger in exchange for private placement shares and
private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa’s initial public offering
will remain (as provided in the documentation for Moringa’s initial public offering) 30 days after the Closing. |
|
● |
Representative Shares.
The lock-up period on all Representative Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) that
are held by EarlyBird will remain (as provided in the documentation for Moringa’s initial public offering) three months after the
Closing. |
|
● |
Note Shares and PIPE Shares.
Note Shares issued to the Sponsor upon conversion of amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the
PIPE Investor will not be subject to any lock-up periods following the Closing. |
|
● |
each person who is the beneficial owner of more than
5% of the outstanding New Silexion ordinary shares; |
|
● |
our named executive officer and directors; and |
|
● |
all of our executive officers and directors as a group.
|
|
Name and Address of Beneficial Owner(1) |
Number of Shares
Beneficially Owned |
Approximate
Percentage of Outstanding
Ordinary Shares |
||||||
|
Directors and Executive Officers of New Silexion: |
||||||||
|
Ilan Hadar |
31,160 |
(2) |
* |
|||||
|
Dror Abramov |
4,425 |
* |
||||||
|
Ruth Alon |
6,037 |
* |
||||||
|
Ilan Levin(3) |
229,624 |
(4) |
2.7 |
% | ||||
|
Avner Lushi(5) |
220,788 |
(6) |
2.6 |
% | ||||
|
Shlomo Noy(7) |
220,788 |
(6) |
2.6 |
% | ||||
|
Amnon Peled |
- |
- |
||||||
|
Dr. Mitchell Shirvan |
21,888 |
(8) |
* |
% | ||||
|
Mirit Horenshtein Hadar, CPA |
6,308 |
* |
||||||
|
|
||||||||
|
All executive officers and directors as a group (8 individuals)
|
520,230 |
6.2 |
% | |||||
|
Five Percent Holders: |
||||||||
|
Hudson Bay Master Fund (9) |
740,741 |
8.1 |
% | |||||
|
Entities affiliated with Anson Advisors Inc and Anson Funds Management LP (10) |
740,741 |
6.4 |
% | |||||
|
CVI Investments, Inc. (11) |
740,766 |
8.1 |
% | |||||
|
* |
Less than 1%. |
|
(1) |
Unless otherwise noted, the business address of each beneficial owner listed
in the above table is c/o Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel 5250606. |
|
(2) |
Includes 14,339 New Silexion ordinary shares issuable upon exercise of options,
at an exercise price of $60.48 per share, all of which are vested and currently exercisable. |
|
|
|
|
(3) |
The shares reported in this row are held of record by the Sponsor, Moringa
Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in footnote
(4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr. Ilan Levin, serves as the sole general partner of each
of the Sponsor and the PIPE Investor. Mr. Levin, a director of New Silexion, is the sole director of that general partner. As a result
of his ownership of that general partner, Mr. Levin possesses sole voting and investment authority with respect to the shares indirectly
held by the Sponsor and the PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held by various
individuals and entities, including Mr. Levin. Mr. Levin disclaims beneficial ownership of the securities held by the Sponsor and the
PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities. The address of each of the entities
beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7th
floor, New York, NY 10177. |
|
(4) |
Consists of the total of: (i) 148,592 New Silexion ordinary shares issued
to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination Agreement); (ii) 39,206 New Silexion ordinary shares
issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 352,857 Moringa
private shares held by it; (iii) 19,603 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor upon the Closing
of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held by the Sponsor
(which New Silexion warrants will be exercisable beginning 30 days after the Closing Date); and (iv) 22,223 New Silexion ordinary shares
issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing. The foregoing beneficial ownership of New
Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following the Closing upon
conversion of amounts owed by New Silexion to the Sponsor under the A&R Sponsor Promissory Note, as the potential number of Note Shares,
and the timing of issuance of Note Shares, cannot be determined in advance. |
|
(5) |
The shares reported in this row consist entirely of New Silexion ordinary
shares held of record by Guangzhou Sino-Israel Biotech Fund (“GIBF”), with respect
to which Mr. Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of GIBF.
|
|
(6) |
Includes 203,971 New Silexion ordinary shares issued to GIBF at the Closing
in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed (China) Ltd., to New Silexion pursuant
to the Chinese Subsidiary Transfer. |
|
(7) |
The shares reported in this row consist entirely of New Silexion ordinary
shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment authority as a result of his serving
as Chief Medical Officer of GIBF. |
|
|
|
|
(8) |
Includes 7,170 New Silexion ordinary shares issuable upon exercise of options,
at an exercise price of $60.48 per share, all of which are vested and currently exercisable. |
| (9) |
Represents 740,741 ordinary shares issuable upon exercise of
warrants issued in connection with the Warrant Repricing. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master
Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which
is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial
ownership over these securities. |
|
(10) |
Represents (i) 577,778 ordinary shares issuable upon exercise
of warrants issued in connection with the Warrant Repricing held by Anson Investments Master Fund LP (“AIMF”) and (ii) 162,963
ordinary shares issuable upon exercise of warrants issued in connection with the Warrant Repricing held by Anson East Master Fund LP (“AEMF”).
Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of AIMF and AEMF, hold voting and dispositive power over
the ordinary shares held by each of AIMF and AEMF. Tony Moore is the managing member of Anson Management GP LLC, which is the general
partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo
each disclaim beneficial ownership of these ordinary shares except to the extent of their pecuniary interest therein. The principal business
address of each of AIMF and AEMF is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
|
|
(11) |
Represents (i) 463,741 ordinary shares issuable upon exercise
of warrant issued in our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed
in connection with the Business Combination. Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. (“CVI”),
has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and
voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI Investments, Inc.is
affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant to the prospectus contained
in the Registration Statement of shares purchased by the investor in this offering. |
|
|
Number of Shares of Ordinary Owned Prior to Offering |
Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus
|
Number of Ordinary Shares Owned After the Offering |
Percentage of Ordinary Shares Owned After the Offering |
||||||||||||
|
CVI Investments, Inc. (1)
|
740,766 |
(2) |
277,000 |
(3) |
463,766 |
(4) |
5.5 |
% | ||||||||
|
Anson Investments Master Fund LP (5)
|
577,778 |
(6) |
577,778 |
(6) |
- |
- |
||||||||||
|
Anson East Master Fund LP (7)
|
162,963 |
(8) |
162,963 |
(8) |
- |
- |
||||||||||
|
Hudson Bay Master Fund Ltd. (9)
|
740,741 |
(10) |
740,741 |
(10) |
- |
- |
||||||||||
|
3i, LP (11) |
150,000 |
(12) |
150,000 |
(12) |
- |
- |
||||||||||
|
Intracoastal Capital LLC (13)
|
240,741 |
(14) |
240,741 |
(14) |
- |
- |
||||||||||
|
Boothbay Absolute Return Strategies, LP (15)
|
15,300 |
(16) |
15,300 |
(16) |
- |
- |
% | |||||||||
|
Orca Capital AG (17)
|
37,000 |
(18) |
37,000 |
(18) |
- |
- |
% | |||||||||
|
KBB Asset Management, LLC (19)
|
20,000 |
(20) |
20,000 |
(20) |
- |
- |
% | |||||||||
|
Michael Vasinkevich (21)
|
265,969 |
(22) |
99,719 |
(23) |
166,250 |
(24) | 1.2 |
% | ||||||||
|
Noam Rubinstein (21)
|
130,651 |
(25) |
48,985 |
(26) |
81,666 |
(27) |
* |
% | ||||||||
|
Craig Schwabe (21)
|
13,998 |
(28) |
5,248 |
(29) |
8,750 |
(30) |
* |
% | ||||||||
|
Charles Worthman (21)
|
4,148 |
(31) |
1,555 |
(32) |
2,593 |
(33) |
* |
% | ||||||||

|
* |
Less than 1% |
|
(1) |
Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. (“CVI”),
has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and
voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI Investments, Inc.is
affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant to the prospectus contained
in the Registration Statement of shares purchased by the investor in this offering. |
|
(2) |
Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in
our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection with the Warrant Repricing
and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed in connection with the
Business Combination. |
|
(3) |
Represents 277,000 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(4) |
Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in
our January 2025 financing and (ii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed
in connection with the Business Combination. |
|
(5) |
Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson
Investments Master Fund LP (“Anson”), hold voting and dispositive power over the ordinary shares held by Anson. Tony Moore
is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo
are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares
except to the extent of their pecuniary interest therein. The principal business address of Anson is Maples Corporate Services Limited,
PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. |
|
(6) |
Represents 577,778 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(7) |
Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson
East Master Fund LP (“Anson”), hold voting and dispositive power over the ordinary shares held by Anson. Tony Moore is the
managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are
directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares except
to the extent of their pecuniary interest therein. The principal business address of Anson is Maples Corporate Services Limited, PO Box
309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. |
|
(8) |
Represents 162,963 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(9) |
Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund
Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which
is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial
ownership over these securities. |
|
(10) |
Represents 740,741 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(11) |
3i Management LLC is the general partner of 3i, LP, and Maier Joshua Tarlow is the
manager of 3i Management LLC. As such, Mr. Tarlow exercises sole voting and investment discretion over securities beneficially owned directly
or indirectly by 3i, LP and 3i Management LLC. Mr. Tarlow disclaims beneficial ownership of the securities beneficially owned directly
by 3i, LP and indirectly by 3i Management LLC. The business address of each of the aforementioned parties is 2 Wooster Street, 2nd Floor,
New York, NY 10013. We have been advised that none of Mr. Tarlow, 3i Management LLC, or 3i, LP is a member of the Financial Industry Regulatory
Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer.
|
|
(12) |
Represents 150,000 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(13) |
Mitchell P. Kopin (“Mr. Kopin”) and Daniel B. Asher (“Mr. Asher”),
each of whom are managers of Intracoastal Capital LLC (“Intracoastal”), have shared voting control and investment discretion
over the securities reported herein that are held by Intracoastal. Asa result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial
ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended(the “Exchange Act”)) of the
securities reported herein that are held by Intracoastal. |
|
(14) |
Represents 240,741 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(15) |
Boothbay Absolute Return Strategies LP, a Delaware limited partnership (the “Fund”),
is managed by Boothbay Fund Management, LLC, a Delaware limited liability company (the “Adviser”). The Adviser, in its capacity
as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all securities held by the Fund.
Ari Glass is the Managing Member of the Adviser. Each of the Fund, the Adviser and Mr. Glass disclaim beneficial ownership
of these securities, except to the extent of any pecuniary interest therein. |
|
(16) |
Represents 15,300 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(17) |
Roman Grodon, Thomas Koenig, and Beate Ruhle-Burkhardt have shared voting control
and investment discretion over the securities reported herein that are held by Orca Capital AG (“Orca Capital”). As a result,
each of Roman Grodon, Thomas Koenig, and Beate Ruhle-Burkhardt may be deemed to have beneficial ownership (as determined under Section
13(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) of the securities reported herein that
are held by Orca Capital. The principal business address of Orca Capital is Sperl-Ring 2, 85276 Hettenshausen, Germany. |
|
(18) |
Represents 37,000 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(19) |
Steven Segal is the natural person voting control and investment discretion over the
securities reported herein. The address of the selling shareholder is 47 Calle Del Sur Palm Coast Fl 32137. |
|
(20) |
Represents 20,000 ordinary shares issuable upon exercise of warrants issued in connection
with the Warrant Repricing. |
|
(21) |
Referenced person is affiliated with Wainwright, a registered broker-dealer with a
registered address of H.C. Wainwright & Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022. Wainwright acted as our placement agent
in our January 2025 financing. Referenced person has sole voting and dispositive power over the securities held, acquired the securities
in the ordinary course of business and, at the time the securities were acquired, the selling stockholder had no agreement or understanding,
directly or indirectly, with any person to distribute such securities. |
|
(22) |
Represents (i) 166,250 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing and (ii) 99,719 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(23) |
Represents 99,719 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(24) |
Represents 166,250 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing. |
|
(25) |
Represents (i) 81,666 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing and (ii) 48,985 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(26) |
Represents 48,985 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(27) |
Represents 81,666 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing. |
|
(28) |
Represents (i) 8,750 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing and (ii) 5,248 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(29) |
Represents 5,248 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(30) |
Represents 8,750 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing. |
|
(31) |
Represents (i) 2,593 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing and (ii) 1,555 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(32) |
Represent 1,555 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with the Warrant Repricing. |
|
(33) |
Represents 2,593 ordinary shares issuable upon exercise of placement agent warrants
issued in connection with our January 2025 financing. |
|
● |
the reported last sale price of the ordinary shares equals or exceeds $162.00
per share (as adjusted for share sub-divisions, share capitalizations, reorganizations and recapitalizations), for any 20 trading days
within a 30 trading day period commencing after the warrants become exercisable and ending on the third business day prior to the notice
of redemption to warrant holders; and |
|
● |
a registration statement is then in effect with respect to the New Silexion
ordinary shares underlying such warrants. |
|
● |
the U.S. Holder’s gain or excess
distribution will be allocated ratably over the U.S. Holder’s holding period for the New Silexion securities; |
|
● |
the amount allocated to the U.S. Holder’s
taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder’s
holding period before the first day of New Silexion’s first taxable year in which New Silexion is a PFIC, will be taxed as
ordinary income; |
|
● |
the amount allocated to other taxable years (or
portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that
year and applicable to the U.S. Holder without regard to the U.S. Holder’s other items of income and loss for such year;
and |
|
● |
an additional amount equal to the interest charge generally
applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable
year of the U.S. Holder. |
|
|
● |
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
|
|
|
|
|
● |
block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and
resell a portion of the block as principal to facilitate the transaction; |
|
|
|
|
|
|
● |
purchases by a broker-dealer as principal and resale by the broker-dealer for their account; |
|
|
|
|
|
|
● |
an exchange distribution in accordance with the rules of the applicable exchange; |
|
|
|
|
|
|
● |
privately negotiated transactions; |
|
|
|
|
|
|
● |
short sales effected after the date the registration statement of which this prospectus is a part is declared
effective by the SEC; |
|
|
|
|
|
|
● |
through the writing or settlement of options or other hedging transactions, whether through an options
exchange or otherwise; |
|
|
● |
broker-dealers may agree with the Selling Securityholders to sell a specified number of such shares
at a stipulated price per share; |
|
|
|
|
|
|
● |
a combination of any such methods of sale; and |
|
|
|
|
|
|
● |
any other method permitted by applicable law. |
INDEX TO FINANCIAL STATEMENTS
TABLE OF CONTENTS
MORINGA ACQUISITION CORP
| Page | ||
| Moringa Acquisition Corp Condensed Consolidated Financial Statements | ||
| Condensed Consolidated Balance Sheets | F-2 | |
| Condensed Consolidated Statements of Operations | F-3 | |
| Condensed Consolidated Statements of Changes in Capital Deficiency | F-4 | |
| Condensed Consolidated Statements of Cash Flows | F-5 | |
| Notes to the Condensed Consolidated Financial Statements | F-6 - F-21 | |
| Moringa Acquisition Corp Audited Financial Statements | ||
| Report of Independent Registered Public Accounting Firm (PCAOB ID # 1309) | F-22 | |
| Balance Sheets | F-23 | |
| Statements of Operations | F-24 | |
| Statements of Changes in Capital Deficiency | F-25 | |
| Statements of Cash Flows | F-26 | |
| Notes to Financial Statements | F-27 - F-39 |
SILEXION THERAPEUTICS CORP
CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||
| Silexion Therapeutics Corp Condensed Consolidated Financial Statements | ||
| Condensed Consolidated Balance Sheets (unaudited) | F-42 - F-44 | |
| Condensed Consolidated Statements of Operations (unaudited) | F-45 | |
| Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (unaudited) | F-46 - F-47 | |
| Condensed Consolidated Statements of Cash Flows (unaudited) | F-48 -F-49 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | F-50 - F64 |
| Silexion Therapeutics Corp Audited Financial Statements | ||
| Report of Independent Registered Public Accounting Firm | F-67 | |
| CONSOLIDATED FINANCIAL STATEMENTS: | ||
| Consolidated Balance Sheets | F-68 -F-69 | |
| Consolidated Statements of Operations | F-70 | |
| Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency | F-71 | |
| Consolidated Statements of Cash Flows | F-72 - F-73 | |
| Notes to Consolidated Financial Statements | F-74 |
F-1
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |||||||||
| Note | 2024 | 2023 | ||||||||
| U.S. Dollars | ||||||||||
| Assets | ||||||||||
| ASSETS: | ||||||||||
| Cash and cash equivalents | ||||||||||
| Investments held in Trust Account | ||||||||||
| Prepaid expenses | ||||||||||
| TOTAL ASSETS | ||||||||||
| Liabilities and shares subject to possible redemption net of capital deficiency | ||||||||||
| LIABILITIES: | ||||||||||
| Accrued expenses | ||||||||||
| Related party | 4 | |||||||||
| Private warrant liability | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| COMMITMENTS AND CONTINGENCIES | 5 | |||||||||
| CLASS
A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: |
||||||||||
| CAPITAL DEFICIENCY: | 7 | |||||||||
| Class
A Ordinary Shares, $ |
||||||||||
| Class
B Ordinary Shares, $ |
||||||||||
| Preferred
Shares, $ |
||||||||||
| Accumulated deficit | ( |
) | ( |
) | ||||||
| TOTAL CAPITAL DEFICIENCY | ( |
) | ( |
) | ||||||
| TOTAL LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY | ||||||||||
| * | Less than one US dollar |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-2
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Note | Six months ended June 30, |
Three
months ended June 30, |
||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||
| U.S. Dollars | U.S. Dollars | |||||||||||||||||
| Except share data | Except share data | |||||||||||||||||
| INTEREST EARNED ON INVESTMENTS HELD IN TRUST ACCOUNT | ||||||||||||||||||
| GENERAL AND ADMINISTRATIVE | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
| CHANGE IN FAIR VALUE OF WARRANT LIABILITY | ( |
) | ( |
) | ||||||||||||||
| NET PROFIT (LOSS) FOR THE PERIOD | ( |
) | ( |
) | ||||||||||||||
| WEIGHTED AVERAGE NUMBER OF CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | 8 | |||||||||||||||||
| NET PROFIT PER CLASS A ORDINARY SHARE SUBJECT TO POSSIBLE REDEMPTION – BASIC AND DILUTED | $ | $ | ||||||||||||||||
| WEIGHTED AVERAGE NUMBER OF NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES | 8 | |||||||||||||||||
| NET LOSS PER NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES – BASIC AND DILUTED | ( |
) | $ | ( |
) | ( |
) | $ | ( |
) | ||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-3
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
| Class A ordinary shares |
Class B ordinary shares |
Total | ||||||||||||||||||||||
|
Number of shares |
Par value |
Number of shares |
Par value |
Accumulated deficit |
capital deficiency |
|||||||||||||||||||
| BALANCE AT December 31, 2022 | ( |
) | ( |
) | ||||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of March 31, 2023 | ( |
) | ( |
) | ||||||||||||||||||||
| Net profit for the period | ||||||||||||||||||||||||
| BALANCE AT March 31, 2023 | ( |
) | ( |
) | ||||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of June 30, 2023 | ( |
) | ( |
) | ||||||||||||||||||||
| Net profit for the period | ||||||||||||||||||||||||
| BALANCE AT June 30, 2023 | ( |
) | ( |
) | ||||||||||||||||||||
| BALANCE AT December 31, 2023 | ( |
) | ( |
) | ||||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of March 31, 2024 | ( |
) | ( |
) | ||||||||||||||||||||
| Net loss for the period | ( |
) | ( |
) | ||||||||||||||||||||
| BALANCE AT March 31, 2024 | ( |
) | ( |
) | ||||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of June 30, 2024 | ( |
) | ( |
) | ||||||||||||||||||||
| Net loss for the period | ( |
) | ( |
) | ||||||||||||||||||||
| BALANCE AT June 30, 2024 | ( |
) | ( |
) | ||||||||||||||||||||
| * | Less than one US dollar |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-4
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six
months ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net profit (loss) for the period | ( |
) | ||||||
| Adjustments to reconcile net profit (loss) to net cash provided by (used in) operating activities: | ||||||||
| Change in the fair value of the private warrant liability | ( |
) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease in prepaid expenses | ||||||||
| Increase (decrease) in related party | ( |
) | ||||||
| Increase (decrease) in accrued expenses | ( |
) | ||||||
| Net cash provided by (used in) operating activities | ( |
) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Partial redemption of Class A ordinary shares subject to possible redemption | - | ( |
) | |||||
| Proceeds from promissory notes – related party | ||||||||
| Net cash provided by (used in) financing activities | ( |
) | ||||||
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT | ( |
) | ||||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF PERIOD | ||||||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF PERIOD | ||||||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT: | ||||||||
| Cash and cash equivalents | ||||||||
| Investments held in trust account | ||||||||
| Total cash, cash equivalents and investments held in a trust account | ||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-5
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
| a. | Organization and General |
Moringa Acquisition Corp (hereafter – the Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter – the Business Combination). The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).
The Company has selected December 31 as its fiscal year end.
| b. | Sponsor and Financing |
The Company’s sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the “Sponsor”).
Refer to Note 7(a) for information regarding the
aggregate withdrawals of approximately $
| c. | The Trust Account |
The proceeds held in the Trust Account are invested
in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset
value of $
The Company complies with the provisions of ASU 2016-18, under which changes in Investments held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments Held in a Trust Account in the Company’s Statements of Cash Flows.
Refer to Note 4(a) for information regarding proceeds received from the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.
F-6
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
| d. | Initial Business Combination |
The Company’s management has broad discretion
with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of
the Public Offering and the Private Placement are intended to be generally applied toward consummating an initial Business Combination.
The initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least
The Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon the completion of the initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business combination or (ii) by means of a tender offer.
If the Company holds a shareholder vote or there is a tender offer for shares in connection with an initial Business Combination, a public shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of two days prior to the general meeting or commencement of the Company’s tender offer, including interest but less taxes payable. As a result, the Company’s Public Class A ordinary shares are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.”
Pursuant to the Company’s amended and restated
memorandum and articles of association, as amended, if the Company is unable to complete the initial Business Combination within 42 months
from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable,
and less up to $
The Sponsor and the Company’s officers and directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to any Class B ordinary share (as described in Note 7) held by them if the Company fails to complete the initial Business Combination within 24 months of the Closing of the Public Offering or during any extended time that the Company has to consummate an initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However, if the Sponsor or any of the Company’s directors or officers acquire any Class A ordinary shares, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the Initial Business Combination within the prescribed time period.
F-7
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
In the event of a liquidation, dissolution or winding up of the Company after an initial Business Combination, the Company’s shareholders are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the ordinary shares. The Company’s shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.
On February 9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter – the First Extension Meeting). At the First Extension Meeting, the Company’s shareholders approved the proposal to adopt, by way of special resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary of the Closing of the Public Offering – i.e., February 19, 2023 to August 19, 2023 (hereafter – the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
On August 18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter – the Second Extension Meeting). At the Second Extension Meeting, the Company’s shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended Mandatory Liquidation Date to August 19, 2024 (hereafter – the Second Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions, and for information regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.
| e. | Substantial Doubt about the Company’s Ability to Continue as a Going Concern |
As of June 30, 2024, the Company had approximately
$
F-8
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
Since its inception date and through the issuance date of these unaudited condensed consolidated financial statements, the Company’s liquidity needs were satisfied through an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company’s ability to continue as a going concern, for the subsequent twelve months following the issuance date of these unaudited condensed consolidated financial statements.
In February 2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics Ltd. (hereafter – Silexion), an Israeli company which is in its developmental stage, dedicated to the development of innovative treatments for pancreatic cancer. Refer to Note 1(f) for further information regarding the Proposed Silexion Merger.
No adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.
| f. | Proposed Business Combination |
On February 21, 2024, the Company, together with its wholly-owned Israeli subsidiary April M.G. Ltd. – which was incorporated due to the original business combination structure, entered into a business combination agreement with Silexion (hereafter – the Proposed Silexion Merger).
The Proposed Silexion Merger is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the Business Combination Agreement, including the approval of the business combination by Silexion’s and the Company’s shareholders, as well as Nasdaq’s approval of the initial listing of the combined company’s securities.
The Proposed Silexion Merger have been unanimously approved by the boards of directors of the Company and Silexion.
On April 3, 2024, the Proposed Silexion Merger contemplated under the original Proposed Silexion Merger agreement was restructured pursuant to the Business Combination Agreement, by and among New Pubco (a newly formed Cayman Islands exempted company), its two newly-formed subsidiaries – Merger Sub 1 and Merger Sub 2 – the Company and Silexion.
F-9
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
As contemplated under the Business Combination Agreement, Merger Sub 2 will merge with and into the Company, with the Company continuing as the surviving company and a wholly-owned subsidiary of New Pubco, and Merger Sub 1 will merge with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned subsidiary of New Pubco. The shareholders and other equity holders of each of the Company and Silexion will receive corresponding securities of New Pubco as consideration in the Prospective Business Combination at set ratios in exchange for their securities of Company and Silexion, respectively. New Pubco will serve as the public company upon completion of the Proposed Business Combination, with its ordinary shares and warrants listed for trading on Nasdaq.
The foregoing description of the Proposed Business Combination, as amended, does not purport to be complete. For further information and access to the full agreement and all other related agreements, refer to the Company’s Current Report on Form 8-K filed with the SEC on April 3, 2024.
In connection with the Proposed Silexion Merger, on May 9, 2024, New Pubco filed with the SEC a Registration Statement on Form S-4, and has subsequently filed amendments on June 24, 2024, July 7, 2024 and July 12, 2024, that include a document that will serve as both a prospectus for the securities to be issued by New Pubco in the Prospective Business Combination to security holders of the Company and Silexion, as well as a proxy statement of the Company for the Company’s extraordinary general meeting at which the Prospective Business Combination and the Business Combination Agreement (among other matters) was presented for approval (see note 9). The SEC staff declared the New Pubco Registration Statement effective on July 16, 2024.
| g. | Impact of War in Israel |
Israel’s current war against the terrorist organization Hamas continued to rage during the second quarter of 2024. The intensity and duration of the war has varied since it began on October 7, 2023. Up to the balance sheet date and subsequently, the war has not had a material effect on the Company. However, the war may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company’s ability to effectively complete the Proposed Business Combination.
F-10
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of Presentation |
The condensed consolidated financial statements herein are unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of the management, necessary for a fair statement of results for the interim period. The results of the operation for the six and three-month periods ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2023 as filed on April 1, 2024, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto of Moringa Acquisition Corp.
| b. | Emerging Growth Company |
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences in accounting standards used.
F-11
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| c. | Cash and cash equivalents |
The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts of cash.
| d. | Class A Ordinary Shares subject to possible redemption |
As discussed in Note 1, all of the
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions. Also, refer to Note 9(c) regarding an additional redemption after the balance sheet date.
| e. | Net profit (loss) per share |
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7, and the Class B ordinary shares (hereafter and collectively – Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject to possible redemption.
In order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in trust account. Then, the accretion is fully allocated to the Class A ordinary shares subject to redemption.
| f. | Concentration of credit risk |
Financial instruments that potentially
subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed
the Federal Depository Insurance Coverage of $
As of June 30, 2024, the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.
F-12
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| g. | Public Warrants |
The Company applied the provisions of ASC 815-40 and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.
| h. | Private Warrant liability |
The Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (“ASC 815”), “Derivatives and Hedging”, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, and any change in fair value is recognized in the Company’s statements of operations. Refer to Note 6 for information regarding the model used to estimate the fair value of the Private Warrants (as defined in Note 3).
| i. | Financial instruments |
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures”, approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
| j. | Use of estimates in the preparation of financial statements |
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company’s financial statements.
| m. | Income tax |
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes (hereafter – ASC 740). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.
F-13
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| n. | Recent accounting pronouncements |
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company’s financial statements.
NOTE 3 - PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In the Initial Public Offering, the Company issued
and sold
Once the Public Warrants become exercisable, the
Company may redeem them in whole and not in part at a price of $
The Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company’s Initial Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares issuable upon exercise thereof) are entitled to registration rights.
The Company paid an underwriting commission of
F-14
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS:
| a. | Promissory Notes |
The Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of the consummation of the Company’s Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and collectively – the Maturity Date).
Second to Fifth Promissory Notes
On August 9, 2021 the Company issued its Second
Promissory Note to the Sponsor, according to which the former may withdraw up to $
In December 2022 the Company issued its Third
and Fourth Promissory Notes, according to which the Company may withdraw up to an aggregate amount of $
On February 8, 2023 the Company issued its Fifth
Promissory Note to the Sponsor, in an amount of up to $
According to the terms of the outstanding Second,
Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $
Sixth Promissory Note
On February 9, 2023 the Company issued its Sixth
Promissory Note to the Sponsor, in an amount of $
Seventh Promissory Note
On June 14, 2023 the Company issued its Seventh
Promissory Note to the Sponsor in an amount of up to $
F-15
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS (continued):
Eighth Promissory Note
On August 18, 2023 the Company issued its Eighth
Promissory Note to the Sponsor, in an amount of approximately $
Ninth Promissory Note
On March 27, 2024, the Company issued its Ninth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $
Tenth Promissory Note
On June 27, 2024, the Company issued its Tenth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $
A&R Promissory Note
Upon the closing of the proposed business combination,
and according to the terms of the amended Silexion Business Combination agreement, all promissory notes shall be converted into one sponsor
promissory note – the A&R Sponsor Promissory Note, which will be subject to a cap of (i) $
| b. | Administrative Services Agreement |
On December 16, 2020, the Company signed an agreement
with the Sponsor, under which the Company shall pay the Sponsor a fixed $
The composition of the Related Party balance as of June 30, 2024 and December 31, 2023 is as follows:
| June 30, 2024 |
December 31, 2023 |
|||||||
| In U.S. dollars | ||||||||
| Promissory notes | ||||||||
| Accrual for Administrative Services Agreement | ||||||||
F-16
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 5 - COMMITMENTS AND CONTINGENCIES:
| a. | Underwriters’ deferred discount |
Under the Business Combination
Marketing Agreement, the Company shall pay an additional fee (hereafter – the Deferred Commission) of
| b. | Advisory and Placement Agent Agreement with Cohen & Company |
Refer to Note 9(d) for information regarding the agreement entered into after the balance sheet date.
| c. | Nasdaq Deficiency Notice |
Third Deficiency Notice
On February 20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter - the Panel), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement.
The Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which was held on April 23, 2024.
On April 23, 2024, the Company participated in a hearing with Nasdaq in which the Company presented its request that Nasdaq provide the Company an additional six months to remedy the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. The Company’s plan for regaining compliance focused on the Company’s efforts to complete its previously disclosed Proposed Business Combination with Silexion. On May 10, 2024, the Company received the results of the hearing, under which Nasdaq approved the Company’s request for a six-month extension— until the Second Extension Date— to remain listed on Nasdaq and complete its proposed business combination.
F-17
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 6 - FAIR VALUE MEASUREMENTS:
The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price).
The fair value hierarchy under ASC 820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Basis for Fair Value Measurement
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;
Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement).
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 by level within the fair value hierarchy:
| Level | June 30, 2024 |
December 31, 2023 |
||||||||
| Assets: | ||||||||||
| Money market funds held in Trust Account | 1 | |||||||||
| Liabilities: | ||||||||||
| Private Warrant Liability | 3 | |||||||||
The estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market’s implied probability for an Initial Business Combination, using the Public Warrant’s market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used to calculate the Private Warrants’ fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table provides quantitative information regarding Level 3 fair value measurements inputs:
| As of June 30, 2024 |
As of December 31, 2023 |
|||||||
| Share price | $ | $ | ||||||
| Strike price | $ | $ | ||||||
| Volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Dividend yield | % | % | ||||||
| Public warrant market price | $ | $ | ||||||
| In U.S dollars | ||||
| Value of warrant liability measured with Level 3 inputs at December 31, 2023 | ||||
| Change in fair value of private warrant liability measured with Level 3 inputs | ||||
| Value of warrant liability measured with Level 3 inputs at June 30, 2024 | ||||
F-18
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 7 - CAPITAL DEFICIENCY:
| a. | Ordinary Shares |
Class A Ordinary Shares
On November 20, 2020 the Company issued
The Company accounted for the issuance of the
Representative Shares as compensation expenses amounting to $
Pursuant to the initial Public Offering and the
concurrent Private Placement that were each effected in two closings – on February 19, 2021 and March 3, 2021 – the Company
issued and sold an aggregate of
The Company classified its
In conjunction with the First and Second
Extensions,
Class B Ordinary Shares
On November 20, 2020, the Company issued
Class B ordinary shares are convertible into non-redeemable Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.
Following the Second Extension Meeting, the Sponsor
converted
| b. | Preferred shares |
The Company is authorized to issue up to
F-19
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 8 - NET PROFIT (LOSS) PER SHARE:
The following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):
| Six months ended June 30, |
Three months ended June 30, |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net profit (loss) for the period | $ | ( |
) | $ | $ | ( |
) | $ | ||||||||
| Less – interest earned on Investment held in Trust Account | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Net loss excluding interest | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Class A ordinary shares subject to possible redemption: | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss excluding interest | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Accretion to Class A ordinary shares subject to possible redemption to redemption amount (“Accretion”) | ||||||||||||||||
| $ | $ | $ | $ | |||||||||||||
| Denominator: | ||||||||||||||||
| weighted average number of shares | ||||||||||||||||
| Net profit per Class A ordinary share subject to possible redemption – basic and diluted | $ | $ | $ | $ | ||||||||||||
| Non-redeemable Class A and B ordinary shares: | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss excluding interest | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Accretion | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | |||||||||
| Denominator: | ||||||||||||||||
| weighted average number of shares | ||||||||||||||||
| Net loss per non-redeemable Class A and B ordinary share – basic and diluted | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
The potential exercise of
Additionally, the effect of the conversion
of the Second, Third, Fourth and Fifth Promissory Notes into an aggregate amount of
As a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.
F-20
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 9 - SUBSEQUENT EVENTS:
| a. | Additional withdrawals under the Promissory Notes |
Since the balance sheet date and up until the
filing date of these financial statements, an aggregate amount of $
| b. | Extraordinary General Meeting and redemption of Class A ordinary shares subject to possible redemption |
On August 6, 2024 the Extraordinary General Meeting
has approved the proposed business combination with Silexion. In connection with the meeting, an additional
| c. | Advisory and Placement Agent Agreement with Cohen & Company |
On July 29, 2024 the Company has entered into agreement with Cohen & Company, for providing capital markets advisory and placement agent services, in connection with both (i) the completion of the proposed business combination with Silexion, and (ii) a private placement of equity, equity-linked, convertible and / or debt securities to be consummated with the business combination.
F-21
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Moringa Acquisition Corp
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Moringa Acquisition Corp (the “Company”) as of December 31, 2023 and 2022, and the related statements of operations, changes in capital deficiency and cash flows for each of the two years in the period ended December 31, 2023, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.
Substantial Doubt about the Company’s Ability to Continue as a Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(e) to the financial statements, the Company has limited cash and has incurred losses since inception. Moreover, if the Company is unable to complete a business combination by August 19, 2024 then the Company will cease all operations except for the purpose of liquidating. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1(e). The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Kesselman & Kesselman
Certified
Public Accountants (Isr.)
A member firm of PricewaterhouseCoopers International Limited
Tel-Aviv,
Israel
April 1, 2024
We have served as the Company’s auditor since 2020.
F-22
MORINGA
ACQUISITION CORP
BALANCE
SHEETS
| Note | December 31, 2023 |
December 31, 2022 |
||||||||
| U.S. Dollars | ||||||||||
| Assets | ||||||||||
| ASSETS: | ||||||||||
| Cash and cash equivalents | ||||||||||
| Investments held in Trust Account | ||||||||||
| Prepaid expenses | ||||||||||
| TOTAL ASSETS | ||||||||||
| Liabilities
and shares subject to possible redemption net of capital deficiency |
||||||||||
| LIABILITIES: | ||||||||||
| Accrued expenses | ||||||||||
| Related party | 4 | |||||||||
| Private warrant liability | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| COMMITMENTS AND CONTINGENCIES | 5 | |||||||||
| CLASS
A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: |
||||||||||
| CAPITAL DEFICIENCY: | 7 | |||||||||
| Class A
Ordinary Shares, $ |
||||||||||
| Class B
Ordinary Shares, $ |
||||||||||
| Preferred
Shares, $ |
||||||||||
| Additional paid-in capital | ||||||||||
| Accumulated deficit | ( |
) | ( |
) | ||||||
| TOTAL CAPITAL DEFICIENCY | ( |
) | ( |
) | ||||||
| TOTAL LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY | ||||||||||
| * | Less than one US dollar. |
The accompanying notes are an integral part of these financial statements.
F-23
MORINGA
ACQUISITION CORP
STATEMENTS OF OPERATIONS
| Note | Year
ended December 31, 2023 |
Year
ended December 31, 2022 |
||||||||||
| U.S. Dollars | ||||||||||||
| Except share data | ||||||||||||
| Interest earned on investments held in trust account | ||||||||||||
| General and administrative | 9 | ( |
) | ( |
) | |||||||
| Change in fair value of Private Warrant liability | ||||||||||||
| Net profit for the year | ||||||||||||
| Weighted average number of Class A Ordinary Shares subject to Possible Redemption | 8 | |||||||||||
| Basic and diluted net profit per Class A Ordinary Shares subject to Possible Redemption | $ | |||||||||||
| Weighted average number of non-redeemable Class A and Class B Ordinary shares | ||||||||||||
| Basic and diluted net loss per non-redeemable Class A and Class B Ordinary shares | $ | ( |
) | ( |
) | |||||||
The accompanying notes are an integral part of these financial statements.
F-24
MORINGA
ACQUISITION CORP
STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
| Class A ordinary shares |
Class B ordinary shares |
Additional | ||||||||||||||||||||||||||
| Number of shares |
Par value |
Number of shares |
Par value |
paid-in capital |
Accumulated deficit |
Total | ||||||||||||||||||||||
| U.S. Dollars (except share data) | ||||||||||||||||||||||||||||
| BALANCE AT December 31, 2021 | ( |
) | ( |
) | ||||||||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of December 31, 2022 | - | - | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
| Net profit for the year | - | - | ||||||||||||||||||||||||||
| BALANCE AT December 31, 2022 | ( |
) | ( |
) | ||||||||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of December 31, 2023 | - | - | ( |
) | ( |
) | ||||||||||||||||||||||
| Conversion of Class B ordinary shares into Class A ordinary shares | ( |
) | ( |
) | ||||||||||||||||||||||||
| Net profit for the year | - | - | ||||||||||||||||||||||||||
| BALANCE AT December 31, 2023 | ( |
) | ( |
) | ||||||||||||||||||||||||
| * | Less than one US dollar. |
The accompanying notes are an integral part of these financial statements.
F-25
MORINGA
ACQUISITION CORP
STATEMENTS OF CASH FLOWS
| Year
ended December 31, 2023 |
Year
ended December 31, 2022 |
|||||||
| U.S. Dollars | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net profit for the year | ||||||||
| Adjustments to reconcile net profit to net cash provided by operating activities: | ||||||||
| Changes in the fair value of the private warrant liability | ( |
) | ( |
) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease in prepaid expenses | ||||||||
| Increase (decrease) in related party | ( |
) | ||||||
| Increase in accrued expenses | ||||||||
| Net cash provided by operating activities | ||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Partial redemption of Class A ordinary shares subject to possible redemption | ( |
) | - | |||||
| Proceeds from a promissory note – related party | ||||||||
| Net cash provided by (used in) financing activities | ( |
) | ||||||
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT | ( |
) | ||||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF YEAR | ||||||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF YEAR | ||||||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT: | ||||||||
| Cash and cash equivalents | ||||||||
| Investments held in trust account | ||||||||
| Total cash, cash equivalents and investments held in a trust account | ||||||||
| SUPPLEMENTARY INFORMATION REGARDING NON-CASH ACTIVITIES: | ||||||||
| Conversion of Class B ordinary shares into Class A ordinary shares | ||||||||
The accompanying notes are an integral part of these financial statements.
F-26
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
| a. | Organization and General |
Moringa Acquisition Corp (hereafter — the Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter — the Business Combination). The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).
All activity for the year ended December 31, 2023 relates to the Company’s search for a target company, as well as attempts to consummate the Proposed Holisto Merger which was terminated on August 8, 2023 as detailed in Note 1(f).
In February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further information regarding the Proposed Business Combination.
The Company has selected December 31 as its fiscal year end.
| b. | Sponsor and Financing |
The Company’s sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the “Sponsor”).
The
registration statement relating to the Company’s Public Offering was declared effective by the United States Securities and
Exchange Commission (the “SEC”) on February 16, 2021. The initial stage of the Company’s Public Offering — the
sale of
| c. | The Trust Account |
The
proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule 2a-7
thereof that maintain a stable net asset value of $
The Company’s complies with the provisions of ASU 2016-18, under which changes in proceeds held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments Held in a Trust Account in the Company’s Statements of Cash Flows.
Refer to Note 4(a) for information regarding proceeds loaned by the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.
| d. | Initial Business Combination |
The
Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although
substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating
an Initial Business Combination. The Initial Business Combination must occur with one or more operating businesses or assets with a fair
market value equal to at least
F-27
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS: (cont.)
The Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon the completion of the Initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business combination or (ii) by means of a tender offer.
If the Company holds a shareholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a public shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of two days prior to the general meeting or commencement of the Company’s tender offer, including interest but less taxes payable. As a result, the Company’s Class A ordinary shares subject to possible redemption are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity”.
Pursuant
to the Company’s amended and restated memorandum and articles of association, if the Company is unable to complete the Initial Business
Combination within 24 months (as was subsequently extended, as described below) from the Closing of the Public Offering, the Company
will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than
ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then
on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $
The Sponsor and the Company’s officers and directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to any Class B ordinary share, including any Class A ordinary share issuable upon conversion of such Class B ordinary shares, and Class A ordinary share (as described in Note 7) held by them if the Company fails to complete the Initial Business Combination within 24 months (as was subsequently extended) of the Closing of the Public Offering or during any extended time that the Company has to consummate an Initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However, if the Sponsor or any of the Company’s directors or officers acquire any Class A ordinary shares subject to possible redemption, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the Initial Business Combination within the prescribed time period.
In the event of a liquidation, dissolution or winding up of the Company after an Initial Business Combination, the Company’s shareholders are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the ordinary shares. The Company’s shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.
F-28
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS: (cont.)
On February 9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter — the First Extension Meeting). At the First Extension Meeting, the Company’s shareholders approved the proposal to adopt, by way of special resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary of the Closing of the Public Offering — i.e., February 19, 2023 to August 19, 2023 (hereafter — the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
On August 18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter — the Second Extension Meeting). At the Second Extension Meeting, the Company’s shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended Mandatory Liquidation Date to August 19, 2024 (hereafter — the Second Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
Refer to Note 4(a) for information regarding proceeds received by the Company from the Sponsor under the Sixth and Eighth Promissory Notes, which were deposited into the Trust Account.
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extension Meetings.
Refer to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.
| e. | Substantial Doubt about the Company’s Ability to Continue as a Going Concern |
As
of December 31, 2023 the Company had approximately $
Since its inception date and through the issuance date of these financial statements, the Company’s liquidity needs were satisfied through an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company’s ability to continue as a going concern, for the subsequent twelve months following the issuance date of these financial statements. In February 2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics Ltd. (hereafter — Silexion). Refer to Note 10(b) for further information regarding the Proposed Business Combination.
No adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.
F-29
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS: (cont.)
| f. | Proposed Business Combination |
On June 9, 2022 the Company entered into a Business Combination Agreement for a proposed business combination (hereafter — the Proposed Holisto Merger) with Holisto Ltd., a company organized under the laws of the State of Israel (hereafter — Holisto) and Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of Holisto.
On August 7, 2023 Holisto notified the Company that it was terminating the Proposed Holisto Merger agreement. The termination became effective as of August 8, 2023. Upon termination of the Proposed Holisto Merger, all rights and obligations of each party to the agreement ceased, except for those obligations of the parties that are intended to survive such termination and which remain in effect in accordance with their respective terms. Neither the Company nor Holisto has any remaining substantive obligation to one another following the above-mentioned termination, as of date of these financial statements.
In February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further information regarding the Proposed Business Combination.
| g. | Impact of War in Israel |
On October 7, 2023 Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.
The intensity and duration of Israel’s current war against Hamas is difficult to predict, as are such war’s economic implications on the business and operations on any target company with which the Company may combine, and on Israel’s economy in general. These events may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company’s ability to effectively complete an Initial Business Combination, or on the operations of an Israel-centered target company with which the Company may combine.
Refer to Note 10(b) for further information regarding the Proposed Business Combination.
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of Presentation |
The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the SEC.
| b. | Emerging Growth Company |
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
F-30
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES: (cont.)
This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences in accounting standards used.
| c. | Cash and cash equivalents |
The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts of cash.
| d. | Class A Ordinary Shares subject to possible redemption |
As
discussed in Note 1(b), all of the
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First Extension Meeting and the Second Extension Meeting.
| e. | Net profit (loss) per share |
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7(a), and the Class B ordinary shares (hereafter and collectively — Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject to possible redemption.
In order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in the Trust Account. Then, any accretion is fully allocated to the Class A ordinary shares subject to redemption.
| f. | Concentration of credit risk |
Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Depository Insurance Coverage of $
As of December 31, 2023 the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.
F-31
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES: (cont.)
| g. | Public Warrants |
The Company applied the provisions of ASC 815-40 and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.
| h. | Private Warrant liability |
The Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (“ASC 815”), “Derivatives and Hedging”, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the Company’s statement of operations. Refer to Note 6 for information regarding the model used to estimate the fair value of the Private Warrants (as defined in Note 3).
| i. | Financial instruments |
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures”, approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
| j. |
Use of estimates in the preparation of financial statements |
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company’s financial statements.
| k. |
Income tax |
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes (hereafter — ASC 740). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.
| l. | Recent accounting pronouncements |
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company’s financial statements.
NOTE 3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In
the initial Public Offering, the Company issued and sold
F-32
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS: (cont.)
Each
Unit (both those sold in the initial Public Offering and in the Private Placement) consists of one Class A ordinary share, $
Once
the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $
The Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company’s Initial Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares issuable upon exercise thereof) are entitled to registration rights.
The
Company paid an underwriting commission of
NOTE 4 — RELATED PARTY TRANSACTIONS:
| a. | Promissory Notes |
The Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of the consummation of the Company’s Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and collectively — the Maturity Date).
First Promissory Note
The First Promissory Note withdrawn was borrowed and repaid in full in early 2021 and has subsequently expired.
Second to Fifth Promissory Notes
On
August 9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $
In
December 2022 the Company issued its Third and Fourth Promissory Notes (hereafter — the Third and Fourth Promissory
Notes), according to which the Company may withdraw up to an aggregate amount of $
F-33
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 4 — RELATED PARTY TRANSACTIONS: (cont.)
On
February 8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $
According
to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $
Sixth Promissory Note
On
February 9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $
Seventh Promissory Note
On
June 14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $
Eighth Promissory Note
On
August 18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $
| b. | Administrative Services Agreement |
On
December 16, 2020 the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $
The composition of the Related Party balance as of December 31, 2023 and 2022 is as follows:
| December 31, 2023 |
December 31, 2022 |
|||||||
| U.S. dollars | ||||||||
| Promissory notes | ||||||||
| Accrual for Administrative Services Agreement | ||||||||
F-34
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 5 — COMMITMENTS AND CONTINGENCIES:
| a. | Underwriters’ Deferred Discount |
Under
the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter — the Deferred Commission)
of
| b. | Nasdaq Deficiency Notices |
First Deficiency Notice
On March 28, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it is not in compliance with Nasdaq Listing Rule 5550(a)(3) (hereafter — the First Deficiency), according to which the Company must satisfy the Minimum Public Holders Rule which requires listed companies to have at least 300 public holders. The Company has submitted its compliance plan on May 11, 2023 which was accepted by Nasdaq, which has then granted an extension of up to 180 calendar days from the date of the notice — until September 24, 2023 — to evidence compliance with the rule.
On September 27, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained compliance with the First Deficiency.
Second Deficiency Notice
On
June 15, 2023 the Company received another notice from Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule 5550(b)(2) (hereafter — the Second Deficiency), according to which the Company must
sustain a market value of listed securities of at least $
NOTE 6 — FAIR VALUE MEASUREMENTS:
Following
the Second Extension Meeting, the Sponsor converted
On November 24, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained compliance with the Second Deficiency.
The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price).
The fair value hierarchy under ASC 820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
F-35
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 6 — FAIR VALUE MEASUREMENTS: (cont.)
Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;
Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement).
Basis for Fair Value Measurement
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2023 by level within the fair value hierarchy:
| Level | December 31, 2023 |
December 31, 2022 |
||||||||||
| Assets: | ||||||||||||
| Money market funds held in Trust Account | 1 | |||||||||||
| Liabilities: | ||||||||||||
| Private warrant liability | 3 | |||||||||||
The estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market’s implied probability for an Initial Business Combination, using the Public Warrant’s market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used to calculate the Private Warrants’ fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table provides quantitative information regarding Level 3 fair value measurements inputs:
| As of December 31, 2023 |
As of December 31, 2022 |
|||||||
| Share price | $ | |
$ | |
||||
| Strike price | $ | $ | ||||||
| Volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Dividend yield | % | % | ||||||
| U.S. dollars | ||||
| Value of warrant liability measured with Level 3 inputs at December 31, 2022 | ||||
| Change in fair value of private warrant liability measured with Level 3 inputs | ( |
) | ||
| Value of warrant liability measured with Level 3 inputs at December 31, 2023 | ||||
F-36
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 7 — CAPITAL DEFICIENCY:
| a. | Ordinary Shares |
Class A Ordinary Shares
On
November 20, 2020 the Company issued
The
Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $
Pursuant
to the initial Public Offering and the concurrent Private Placement that were each effected in two closings — on February 19,
2021 and March 3, 2021 — the Company issued and sold an aggregate of
The
Company classified its
In
conjunction with the First and Second Extensions,
Class B Ordinary Shares
On
November 20, 2020 the Company issued
Class B ordinary shares are convertible into non-redeemable Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.
Refer to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares following the Second Extension Meeting.
| b. | Preferred shares |
The
Company is authorized to issue up to
F-37
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 8 — NET PROFIT (LOSS) PER SHARE:
The following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):
| Year ended December 31, |
||||||||
| 2023 | 2022 | |||||||
| Net profit for the year | $ | $ | ||||||
| Less – interest earned on Investment held in Trust Account | ( |
) | ( |
) | ||||
| Net loss excluding interest | $ | ( |
) | $ | ( |
) | ||
| Class A ordinary shares subject to possible redemption: | ||||||||
| Numerator: | ||||||||
| Net loss excluding interest | $ | ( |
) | $ | ( |
) | ||
| Accretion to Class A ordinary shares subject to possible redemption to redemption amount (“Accretion”) | ||||||||
| $ | $ | |||||||
| Denominator: | ||||||||
| Weighted average number of shares | ||||||||
| Basic and diluted net profit per Class A ordinary share subject to possible redemption | $ | $ | ||||||
| Non-redeemable Class A and B ordinary shares: | ||||||||
| Numerator: | ||||||||
| Net loss excluding interest | $ | ( |
) | $ | ( |
) | ||
| Accretion | ( |
) | - | |||||
| (1,147,180 | ) | (248,806 | ) | |||||
| Denominator: | ||||||||
| Weighted average number of shares | ||||||||
| Basic and diluted net loss per non-redeemable Class A and B ordinary share | $ | ( |
) | $ | ( |
) | ||
The
potential exercise of
Additionally,
the effect of the conversion of the Second, Third, Forth and Fifth Promissory Notes into an aggregate amount of
As a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.
F-38
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 9 — GENERAL AND ADMINISTRATIVE:
The formation and other operating expenses for the years ended December 31, 2023 and 2022 are as follows:
| December 31, 2023 |
December 31, 2022 |
|||||||
| U.S. dollars | ||||||||
| Legal expenses | ||||||||
| Audit, bookkeeping and accounting | ||||||||
| Professional services | ||||||||
| Management fees | ||||||||
| Insurance | ||||||||
| Nasdaq fees | ||||||||
| Other | ||||||||
NOTE 10 — SUBSEQUENT EVENTS:
| a. | Nasdaq Deficiency Note |
On February 20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter — the Panel), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement.
The Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which is scheduled to take place on April 23, 2024.
| b. | Proposed Business Combination |
On February 21, 2024, the Company, together with its wholly-owned Israeli subsidiary (hereafter — the Merger Sub), entered into a business combination agreement (hereafter — the BCA) with Silexion Therapeutics Ltd., an Israeli company (hereafter — Silexion).
The Business Combination is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the BCA, including the approval of the Business Combination by Silexion’s and the Company’s shareholders, and Nasdaq approval of the initial listing of the combined company’s securities.
Headquartered
in Israel, Silexion is a clinical-stage, oncology-focused biotechnology company that develops innovative treatments for unsatisfactorily
treated solid tumor cancers which have a mutated KRAS oncogene. The Business Combination values Silexion at a pre-transaction equity value
of $
The BCA and the Business Combination have been unanimously approved by the boards of directors of the Company and Silexion.
F-39
|
Page | |
|
CONSOLIDATED
FINANCIAL STATEMENTS: |
|
|
F-42
- F-44 | |
|
F-45 | |
|
F-46
- F-47 | |
|
F-48
- F-49 | |
|
F-50
- F-64 |
|
September
30, |
December
31 |
|||||||
|
2024
|
2023
|
|||||||
|
U.S.
dollars in thousands |
||||||||
|
Assets
|
||||||||
|
CURRENT
ASSETS: |
||||||||
|
Cash
and cash equivalents |
$
|
|
$
|
|
||||
|
Restricted
cash |
|
|
||||||
|
Prepaid
expenses |
|
|
||||||
|
Other
current assets |
|
|
||||||
|
TOTAL
CURRENT ASSETS |
|
|
||||||
|
NON-CURRENT
ASSETS: |
||||||||
|
Restricted
cash |
|
|
||||||
|
Long-term
deposit |
|
|
||||||
|
Property
and equipment, net |
|
|
||||||
|
Operating
lease right-of-use asset |
|
|
||||||
|
TOTAL
NON-CURRENT ASSETS |
|
|
||||||
|
TOTAL
ASSETS |
$
|
|
$
|
|
||||
|
September
30, |
December
31 |
|||||||
|
2024
|
2023
|
|||||||
|
U.S.
dollars in thousands |
||||||||
|
Liabilities
and redeemable convertible preferred shares, net of capital deficiency |
||||||||
|
CURRENT
LIABILITIES: |
||||||||
|
Trade
payables |
$
|
|
$
|
|
||||
|
Current
maturities of operating lease liability |
|
|
||||||
|
Warrants
to preferred shares (including $ |
|
|
||||||
|
Employee
related obligations |
|
|
||||||
|
Accrued
expenses and other account payable |
|
|
||||||
|
Private warrants to purchase
ordinary shares |
|
|
||||||
|
Underwriters
Promissory Note |
|
|
||||||
|
TOTAL
CURRENT LIABILITIES |
|
|
||||||
|
NON-CURRENT
LIABILITIES: |
||||||||
|
Long-term
operating lease liability |
|
|
||||||
|
Underwriters
Promissory Note |
|
|
||||||
|
Promissory
note - related party |
|
|
||||||
|
TOTAL
NON-CURRENT LIABILITIES |
$
|
|
$
|
|
||||
|
TOTAL
LIABILITIES |
$
|
|
$
|
|
||||
|
COMMITMENTS
AND CONTINGENT LIABILITIES |
||||||||
|
REDEEMABLE
CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS: |
||||||||
|
Convertible
Series A Preferred Shares (NIS |
||||||||
|
Convertible
Series A-1 Preferred Shares (NIS |
||||||||
|
Convertible
Series A-2 Preferred Shares (NIS |
||||||||
|
Convertible
Series A-3 Preferred Shares (NIS |
||||||||
|
Convertible Series A-4
Preferred Shares (NIS |
||||||||
|
TOTAL
REDEEMABLE CONVERTIBLE PREFERRED SHARES |
|
|
||||||
|
CONTINGENTLY
REDEEMABLE NON-CONTROLLING INTERESTS |
|
|
||||||
|
TOTAL
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS |
$
|
|
$
|
|
||||
|
September
30, |
December
31, |
|||||||
|
2024
|
2023
|
|||||||
|
U.S.
dollars in thousands |
||||||||
|
CAPITAL
DEFICIENCY: |
||||||||
|
Ordinary
shares ($
|
|
|
||||||
|
Additional
paid-in capital |
|
|
||||||
|
Accumulated
deficit |
(
|
)
|
(
|
)
| ||||
|
TOTAL
CAPITAL DEFICIENCY |
$
|
(
|
)
|
$
|
(
|
)
| ||
|
TOTAL
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
|
$
|
(
|
)
|
$
|
|
|||
|
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE |
||||||||
|
PREFERRED
SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY |
$
|
|
$
|
|
||||
|
Nine
months ended
September
30 |
Three
months ended
September
30, |
|||||||||||||||
|
2024
|
2023
|
2024
|
2023
|
|||||||||||||
|
U.S.
dollars in
thousands
|
U.S.
dollars in
thousands
|
U.S.
dollars in
thousands
|
||||||||||||||
|
OPERATING
EXPENSES: |
||||||||||||||||
|
Research
and development (including $ |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
General
and administrative (including $ |
|
|
|
|
||||||||||||
|
TOTAL
OPERATING EXPENSES |
|
|
|
|
||||||||||||
|
OPERATING
LOSS |
|
|
|
|
||||||||||||
|
Financial
expenses (income), (including $( |
|
|
|
|
||||||||||||
|
LOSS
BEFORE INCOME TAX |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
INCOME
TAX |
|
|
|
|
||||||||||||
|
NET
LOSS |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Attributable to:
|
||||||||||||||||
|
Equity holders of the
Company |
$
|
|
$
|
|
$
|
|
$ |
|
||||||||
|
Non-controlling interests
|
|
|
|
|
||||||||||||
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||
|
LOSS
PER SHARE, BASIC AND DILUTED |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
WEIGHTED
AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE |
|
|
|
|
||||||||||||
|
Redeemable
Convertible Preferred Shares |
Ordinary
shares |
Additional paid-in Capital |
Accumulated
deficit |
Total
capital
deficiency
|
Total
redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Series
A preferred shares |
Series
A-1 preferred shares |
Series
A-2 preferred shares |
Series
A-3 preferred shares |
Series
A-4 preferred shares |
Contingently
redeemable non-controlling
interests
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AT JANUARY 1, 2023 |
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
|
$
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||||||||||||||||||||||||||||||
|
CHANGES
DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2023 (unaudited): |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance
of Preferred A-4 shares, net of issuance cost |
|
$
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based
compensation |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net
loss |
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AS OF SEPTEMBER 30, 2023 |
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AT JANUARY 1, 2024 |
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||||||||||||||||||||||||||||||
|
CHANGES
DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 (unaudited): |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exercise
of options |
|
** |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based
compensation |
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance
of convertible preferred shares upon net exercise of warrants |
|
|
|
-
|
- |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net
loss |
(
|
)
|
|
(
|
)
|
(
|
)
|
(
|
)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Conversion
of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
|
Issuance
of ordinary shares upon Transactions (see Note 1(d)) |
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance
of ordinary shares for ELOC holders |
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AS OF SEPTEMBER 30, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
| |||||||||||||||||||||||||||||||||||||||||||
|
Redeemable
Convertible Preferred Shares |
Ordinary
shares |
Additional paid-in Capital |
Accumulated
deficit |
Total
capital deficiency |
Total
redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Series
A preferred shares |
Series
A-1 preferred shares |
Series
A-2 preferred shares |
Series
A-3 preferred shares |
Series
A-4 preferred shares |
Contingently
redeemable non-controlling
interests
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AT JUNE 30, 2023 |
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||||||||||||||||||||||||||||
|
CHANGES
DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2023 (unaudited): |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance
of Preferred A-4 shares, net of issuance cost |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based
compensation |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net
loss |
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AS OF SEPTEMBER 30, 2023 |
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
| ||||||||||||||||||||||||||||||||||||||
|
BALANCE
AT JUNE 30, 2024 |
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||||||||||||||||||||||||||||||
|
CHANGES
DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 (unaudited):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based
compensation |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance
of convertible preferred shares upon net exercise of warrants |
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net
loss |
(
|
)
|
|
(
|
)
|
(
|
)
|
(
|
)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Conversion
of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
|
Issuance
of ordinary shares upon Transactions (see Note 1(d)) |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance
of ordinary shares for ELOC holders, net of issuance cost, see Note 3(d) |
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE
AS OF SEPTEMBER 30, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
| |||||||||||||||||||||||||||||||||||||||||||
|
Nine months ended
September 30, |
Three months ended
September 30 |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
U.S. dollars in thousands |
U.S. dollars in thousands |
|||||||||||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||||||||||
|
Net loss |
$ |
(
|
) |
$ |
(
|
) |
$ |
(
|
) |
$ |
(
|
) | ||||
|
Adjustments required to reconcile loss to net cash used in operating
activities: |
||||||||||||||||
|
Depreciation |
|
|
|
|
||||||||||||
|
Share-based compensation expenses |
|
|
|
|
||||||||||||
|
Non-cash financial expenses |
|
|
|
|
||||||||||||
|
Gain on disposal of property and equipment |
|
(
|
) |
|
(
|
) | ||||||||||
|
Loss from lease termination |
|
|
|
|
||||||||||||
|
Changes in operating assets and liabilities: |
||||||||||||||||
|
Increase (decrease) in prepaid expenses |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
|
Increase (decrease) in other receivables |
(
|
) |
|
(
|
) |
|
||||||||||
|
Increase (decrease) in trade payable |
|
|
|
|
||||||||||||
|
Net change in operating lease |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
|
Increase (decrease) in employee related obligations |
|
(
|
) |
|
(
|
) | ||||||||||
|
Increase (decrease) in accrued expenses |
(
|
) |
(
|
) |
(
|
) |
|
|||||||||
|
Net cash used in operating activities |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||||||||||
|
Proceeds from short-term deposit |
|
|
|
|
||||||||||||
|
Purchase of property and equipment |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
|
Proceeds from Sale of property and equipment |
|
|
|
|
||||||||||||
|
Net cash provided by (used in (investing activities |
(
|
) |
|
(
|
) |
|
||||||||||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||||||||||
|
Proceeds from issuance of preferred shares and warrants, net of
issuance costs |
|
|
|
|
||||||||||||
|
Proceeds from issuance of ordinary shares (ELOC) |
|
|
|
|
||||||||||||
|
Cash received from Transactions upon the effectiveness of the SPAC
Merger |
|
|
|
|
||||||||||||
|
Net cash provided by financing activities |
|
|
|
|
||||||||||||
|
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
CASH |
(
|
) |
(
|
) |
|
(
|
) | |||||||||
|
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
AND RESTRICTED CASH |
(
|
) |
(
|
) |
|
(
|
) | |||||||||
|
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED
CASH AT BEGINNING OF PERIOD |
|
|
|
|
||||||||||||
|
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED
CASH AT END OF PERIOD |
|
$ |
|
|
|
|||||||||||
F-48
SILEXION
THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
Nine months ended
September 30, |
Three months ended
September 30 |
|||||||||||||||
| 2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
U.S. dollars in thousands |
U.S. dollars in thousands |
|||||||||||||||
|
Appendix A – RECONCILIATION
OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS: |
||||||||||||||||
|
Cash and cash equivalents |
|
|
|
|
||||||||||||
|
Restricted cash |
|
|
|
|
||||||||||||
|
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
|
Appendix B
- SUPPLEMENTARY INFORMATION: |
||||||||||||||||
|
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
|
||||||||||||||||
|
Operating lease termination |
$ |
(
|
) |
$ |
|
$ |
(
|
) |
$ |
|
||||||
|
Conversion of preferred shares |
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
|
Conversion of warrants to preferred shares on a cashless basis |
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
|
Conversion of non-controlling interests |
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
|
SUPPLEMENTAL DISCLOSURES OF CASH
FLOW INFORMATION: |
||||||||||||||||
|
Interest received |
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-49
SILEXION THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
| a. |
Silexion Therapeutics Corp (“New Silexion”)
(hereinafter -"the Company" or the “combined company”) is a newly formed entity that was formed for the purpose of effecting
the Transactions (see below), and now serves as a publicly-traded holding company of its subsidiaries — including Moringa Acquisition
Corp (“Moringa” or “the SPAC”), a Cayman Islands exempted company and Silexion Therapeutics Ltd. (formerly known
as Silenseed Ltd.) (“Silexion”), an Israeli limited company— after the closing of the Transactions (the “Closing”).
|
| b. |
Financial Information Presented:
|
| c. |
Subsidiaries: |
| 1. |
Silenseed
(China) Ltd. On April 28, 2021, Silexion (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel
Biotech Investment Fund (“GIBF”) to establish a new company in China. On June 15, 2021 a company was established in China,
named Silenseed (China) Ltd. (hereinafter - the "Subsidiary"). As of September 30, 2024, following transfer of all interests in the Subsidiary
to the Company as part of the Transactions, the Company owns (directly or indirectly)
|
| 2. |
Moringa.
Prior to the Transactions, Moringa’s class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market
(Nasdaq: MACA and MACAW). As part of the Transactions, Moringa merged with a wholly-owned subsidiary of the Company and now serves as
an inactive, wholly-owned subsidiary of the Company. |
| 3. |
Silexion.
Silexion was incorporated in Israel and began its operations on November 30, 2008. Since its incorporation, Silexion has been engaged
in
|
| 4. |
The Company, the Subsidiary, Moringa and Silexion
are together referred to hereinafter as “the Group”. |
| d. |
On April 3, 2024, Silexion entered into an Amended
and Restated Business Combination Agreement (hereinafter, “A&R BCA”) with the SPAC, New Silexion, August M.S. Ltd. an
Israeli company and wholly-owned subsidiary of New Silexion (“Merger Sub 1”), and Moringa Acquisition Merger Sub Corp, a Cayman
Islands exempted company and wholly-owned subsidiary of New Silexion (“Merger Sub 2”). Under the A&R BCA, both Silexion
and the SPAC were toi become wholly-owned subsidiaries of New Silexion, which was to become a publicly-held, Nasdaq-listed entity
(the A&R BCA and related transactions: the “Transactions”). |
F-50
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE 1 - GENERAL (continued):
| e. |
In connection with the closing of the Transactions,
the ordinary shares and warrants of New Silexion are now listed on the Nasdaq Global Market and began trading under the symbols “SLXN”
and “SLXNW”, respectively. |
| f. |
For more information on instruments issued as
part of the Transactions, see Note 3. |
| g. |
The Transactions were accounted for as a reverse
recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer and
the SPAC was treated as the “acquired” company for financial reporting purposes. Silexion was determined to be the accounting
acquirer based on evaluation of the following facts and circumstances: |
F-51
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE 1 - GENERAL (continued):
| h. |
In October 2023, Hamas terrorists infiltrated
Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack,
Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.
|
| i. |
Going concern:
|
F-52
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
|
The
Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various
financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses
and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding.
Under
these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about
the Company’s ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
The unaudited condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable
to continue as a going concern (see Note 1 (d)). |
| a. |
Unaudited Condensed Financial
Statements |
| b. |
Use of estimates
|
F-53
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
| c. |
Restricted cash
|
| d. |
Fair value measurement
|
| Level 1: |
Quoted prices (unadjusted) in active markets that
are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
|
| Level 2: |
Observable prices that are based on inputs not
quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.
|
| Level 3 |
Unobservable inputs are used when little or no
market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. |
| e. |
Concentration of credit
risks |
| f. |
Loss per share
|
F-54
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
| g. |
Contracts over Ordinary
Shares |
The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. When a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately before the reclassification. The Redeemable Convertible Preferred Shares were converted into Ordinary Shares in the framework of the recapitalization transaction as described in note 1(d).
| h. |
Promissory Notes
|
F-55
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
| i. |
New accounting pronouncements:
|
| 1) |
In November 2023, the FASB issued ASU No. 2023-07 Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily
through enhanced disclosures about significant segment expenses. The ASU also require that a public entity that has a single reportable
segment to provide all the disclosures required by the amendments and all existing segment disclosures in Topic 280. The ASU is effective
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The
Company is currently evaluating this ASU to determine its impact on the Company's segment disclosures. |
| 2) |
In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for
the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option. The Company
is in the process of assessing the impacts and method of adoption. |
| 3) |
In November 2024, the FASB issued ASU No. 2024-03 Income
Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures
about a public business entity’s expenses and provides more detailed information about the types of expenses in commonly presented
expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts
of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost
of sales, SG&A and research and development). The ASU is effective for fiscal years beginning after December 15, 2026, and interim
periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this
ASU to determine its impact on the Company's disclosures. |
| a. |
Underwriters Promissory
Note
Prior
to the Closing, Moringa reached agreement with EarlyBird Capital, Inc. (“EarlyBird”) on the reduction, to $
The
EarlyBird Convertible Note bears interest at a rate of
New
Silexion is entitled to voluntarily prepay any additional part of, or all of, the principal and accrued interest, in one or more installments
without penalty, prior to the maturity date. |
F-56
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
|
EarlyBird, in turn, may
elect, at its sole discretion, at any time on or prior to the maturity date, to elect to convert all or part of the then outstanding principal
and/or accrued interest under the EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal
to
As of the date of this
report, the Company repaid $ |
| b. |
Sponsor Promissory Note
Effective
as of the Closing, New Silexion issued to the Sponsor in replacement in their entirety of all previously existing promissory notes issued
by Moringa to the Sponsor from its IPO until the Closing, an amended and restated promissory note (the “A&R Sponsor Promissory
Note”) in an amount of $
As
of the date of this report, the Company has neither repaid, nor converted into New Silexion ordinary shares, any principal amounts outstanding
under the Sponsor Promissory Note. |
| c. |
PIPE Financing
In
connection with, and immediately prior to the Closing of the Transactions, Moringa raised $ |
| d. |
ELOC Financing
In
connection with the Closing, New Silexion entered into an ordinary share purchase agreement, effective as of the Closing Date (the “ELOC
Agreement”), for an equity line of credit (the “ELOC”) with White Lion Capital, LLC (the “ELOC Investor”),
whereby New Silexion will be able to request to sell to the ELOC Investor, and the ELOC Investor will be required to purchase, via private
placement transactions, up to $ |
F-57
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
|
Purchase
price is determined with reference to either the lowest daily volume-weighted average price of the Company’s Ordinary Shares during
a period of three consecutive business days ending on the notice date times
Pursuant
to the ELOC Agreement, New Silexion agreed, among other things, that if New Silexion’s sales to the ELOC Investor under the ELOC
exceed
In
consideration for the commitments of the ELOC Investor, New Silexion agreed to issue to the ELOC Investor an aggregate of $
During
the three months ended September 30, 2024, the Company sold |
| e. |
SPAC Warrants
On
the Closing Date, Moringa, New Silexion and Continental Stock Transfer & Trust Company (“CST”) entered into a certain
Assignment, Assumption and Amendment Agreement (the “New Warrant Agreement”). The New Warrant Agreement amended Moringa’s
Warrant Agreement, dated as of February 19, 2021, to provide for the assignment by Moringa of all its rights, title and interest in the
warrants of Moringa to New Silexion.
Upon
Closing, New Silexion assumed
The
Company recognized a net liability, measured at fair value through profit or loss, from the Transactions (see also Note 2). As such, transaction
costs related to the Transactions were expensed as incurred.
The
Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBird or their respective
affiliates, the Private Warrants: (1) will not be redeemable by the Company; (2) could not (subject to certain limited exceptions), be
transferred, assigned or sold by the holders thereof until 30 days after the Closing; (3) may be exercised by the holders thereof on a
cashless basis; and (4) are entitled to registration rights. |
F-58
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
| a. |
Research and development
expenses: |
|
Nine months ended
September 30, |
Three months ended
September 30, |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
U.S. dollars in thousands |
U.S. dollars in thousands |
|||||||||||||||
|
Payroll and related expenses |
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
|
Share-based compensation expenses |
|
|
|
|
||||||||||||
|
Subcontractors and consultants |
|
|
|
|
||||||||||||
|
Materials |
|
|
|
|
||||||||||||
|
Rent and maintenance |
|
|
|
|
||||||||||||
|
Travel expenses |
|
|
|
|
||||||||||||
|
Other |
|
|
|
|
||||||||||||
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||
| b. |
General and administrative expenses: |
|
Payroll and related expenses |
$ |
|
$ |
|
$ |
|
$ |
|
||||||||
|
Share-based compensation expenses |
|
|
|
|
||||||||||||
|
Professional services |
|
|
|
|
||||||||||||
|
Depreciation |
|
|
|
|
||||||||||||
|
Rent and maintenance |
|
|
|
|
||||||||||||
|
Patent registration |
|
|
|
|
||||||||||||
|
Travel expenses |
|
|
|
|
||||||||||||
|
Other |
|
|
|
|
||||||||||||
|
$ |
|
$ |
|
$ |
|
$ |
|
| c. |
Financial expense, net: |
|
Change in fair value of financial liabilities measured at fair value |
$ |
(
|
) |
$ |
(
|
) |
$ |
(
|
) |
$ |
|
|||||
|
Issuance costs |
|
|
|
|
||||||||||||
|
Loss upon entering Transactions |
||||||||||||||||
|
Interest income |
(
|
) |
(
|
) |
|
(
|
) | |||||||||
|
Foreign currency exchange loss, net |
|
|
|
|
||||||||||||
|
Other |
|
|
|
|
||||||||||||
|
Total financial expense, net |
$ |
|
$ |
|
$ |
|
$ |
|
| a. |
On August 15, 2024, the
Company vacated its office spaces and facilities in Israel. On September 8, 2024, an early termination agreement for the operating lease
was signed with the landlord, which included a termination penalty. As a result, the Company derecognized the right-of-use asset and the
lease liability in its financial statements, recording a loss of $ |
| b. |
On September 26, 2024 the Company signed a new
lease agreement for an office in Israel starting November 1, 2024 and ending on October 31, 2026. The Company will pay a monthly payment
of $ |
F-59
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE 6 - WARRANTS TO PURCHASE PREFERRED SHARES:
NOTE 7 - SHARE-BASED COMPENSATION:
|
Expected volatility
|
|
%
| ||
|
Assumptions regarding
the price of the underlying shares: |
||||
|
Probability of an IPO
scenario (including de-SPAC transaction) |
|
%
| ||
|
Expected time to IPO
(including de-SPAC transaction) (years) |
|
|||
|
Probability of other
liquidation events |
|
%
| ||
|
Expected time to liquidation
(years) |
|
|||
|
Expected return on Equity
|
|
%
|
F-60
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
|
Below
is a summary of the Company's (or for periods prior to the Closing of the Transactions, Silexion’s) stock-based compensation activity
and related information with respect to options granted to employees and non-employees for the nine month period ended September 30, 2024:
|
|
Number
of options |
Weighted-average
exercise price (in U.S. dollars) |
Weighted-
average remaining contractual term
(in
years) |
Aggregate
intrinsic
value
|
|||||||||||||
|
Outstanding at January
1, 2024 |
|
$
|
|
|
$
|
|
||||||||||
|
Granted
|
|
|
-
|
-
|
||||||||||||
|
Exercised
|
(
|
)
|
$
|
|
(
|
)
|
$
|
|
||||||||
|
Forfeited
|
(
|
)
|
$
|
|
(
|
)
|
-
|
|||||||||
|
Expired
|
(
|
)
|
$
|
|
-
|
-
|
||||||||||
|
Outstanding at September
30, 2024 |
|
$
|
|
|
-
|
|||||||||||
|
Exercisable at September
30, 2024 |
|
$
|
|
|
-
|
|||||||||||
|
Vested and expected to
vest at September 30, 2024 |
|
$
|
|
|
-
|
|||||||||||
|
Up to September 30, 2024
and for the year ended December 31, 2023 no options were granted. |
|
Nine
months ended
September
30, |
Three
months ended
September
30, |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
|
Research and development
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
General and administrative
|
|
|
|
|
||||||||||||
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||
NOTE 8 - FAIR VALUE MEASUREMENTS:
|
Financial
instruments measured at fair value on a recurring basis
The Company’s (or,
for periods prior to the Closing of the Transactions, Silexion’s) assets and liabilities that are measured at fair value as of September
30, 2024, and December 31, 2023, are classified in the tables below in one of the three categories described in “Note 2 –
Fair value measurement”: |
|
September
30, 2024 |
||||||||
|
Level
3 |
Total
|
|||||||
|
Financial
Liabilities |
||||||||
|
Private
Warrants to purchase ordinary shares |
$
|
|
$
|
|
||||
|
Promissory
Notes |
$
|
|
$
|
|
||||
|
December
31, 2023 |
||||||||
|
Level
3 |
Total
|
|||||||
|
Financial
Liabilities |
||||||||
|
Warrants
to preferred shares |
$
|
|
$
|
|
||||
F-61
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
|
The following is a roll
forward of the fair value of liabilities classified under Level 3: |
|
Nine
months ended
September
30, 2024 |
Three
months ended
September
30, 2024 |
|||||||||||||||||||||||
|
Warrants
to preferred shares |
Warrants
to Ordinary shares |
Promissory
Notes |
Warrants
to preferred shares |
Warrants
to Ordinary shares |
Promissory
Notes
|
|||||||||||||||||||
|
Fair value at the beginning
of the period |
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
|
Issuance
|
|
|
|
|
|
|
||||||||||||||||||
|
Change in fair value
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
| |||||||||||||
|
Conversion
|
(
|
)
|
|
|
(
|
)
|
|
|
||||||||||||||||
|
Fair value at the end
of the period |
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
|
Nine
months ended September 30, 2023 |
Three
months ended September 30, 2023 |
|||||||
|
Warrants
to preferred share |
Warrants
to preferred shares |
|||||||
|
Fair value at the beginning
of the period |
$
|
|
$
|
|
||||
|
Issuance
|
|
|
||||||
|
Change in fair value
|
|
|
||||||
|
Fair value at the end
of the period |
$
|
|
$
|
|
||||
|
ELOC
agreement
As the ELOC agreement
is in substance a purchased call option over the Company’s own shares at a price mentioned in Note 3(d), the fair value of this
agreement will generally be approximately zero, until the Company sells shares under the agreement. Once the Company sells share under
the agreement, the difference between cash raised (net of transaction costs) and the closing price of the Ordinary Shares as of the date
of their issuance is recognized as financing income or expenses.
Fair value gain and losses
arising from ELOC agreement are measured with reference to the spot price of the Company’s shares sold less consideration receivable
from the investor.
Warrant
to preferred shares
The fair value of Silexion’s
warrant to purchase preferred shares as of September 30, 2023 and December 31, 2023 was estimated using a hybrid model in order to reflect
two scenarios: (1) an IPO event (including de-SPAC transaction) and (2) other liquidation events. For further details see Note 12 in the
annual consolidated financial statements.
The valuation under the
‘other liquidation events’ scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation,
which treats the financial instruments in
Silexion’s equity as contingent claims whose future payoff depends on Silexion’s future equity value. Silexion’s entire
equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.
Promissory
Notes
In measuring the fair
value of the Company’s Promissory Notes, a discount rate of |
F-62
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
|
Warrants
over ordinary shares
A Black-Scholes-Merton
model with Level 3 inputs was used to calculate the warrants’ fair value. Inherent in a Black-Scholes-Merton model are assumptions
related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected
peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is
based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants.
The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical
rate, which the Company anticipates remaining at zero.
The following table provides
quantitative information regarding Level 3 fair value measurements inputs of the warrants: |
|
September 30,
|
August 15,
|
|||||||
|
2024
|
2024
|
|||||||
|
Volatility
|
|
%
|
|
%
| ||||
|
Dividend yield
|
|
%
|
|
%
| ||||
|
Financial
instruments not measured at fair value
The carrying amounts
of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the
short-term maturity of such instruments. |
|
The following table sets
forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in
thousands, except per share data): |
|
Nine
months ended
September
30, |
Three
months ended
September
30, |
|||||||||||||||
|
2024
|
2023 |
2024
|
2023 | |||||||||||||
|
Numerator:
|
||||||||||||||||
|
Net
loss |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Net
loss attributable to ordinary shareholders, basic and diluted: |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Denominator:
|
||||||||||||||||
|
Weighted-average
shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted |
|
|
|
|
||||||||||||
|
Net
loss per share attributable to ordinary shareholders, basic and diluted |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Basic loss per share
is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the
period, including fully vested pre-funded options for the Company’s (or Silexion’s, as applicable) ordinary shares at an exercise
price of $ As of September 30, 2024
and September 30, 2023, the basic loss per share calculation included a weighted average number of
|
F-63
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE 9 - NET LOSS PER SHARE (continued):
|
The following instruments
were not included in the computation of diluted earnings per share because of their anti-dilutive effect: |
| - |
Redeemable convertible preferred shares;
|
| - |
Warrants to purchase redeemable convertible preferred
shares; |
| - |
Share-based compensation issuable at substantial
consideration; |
| - |
Private Warrants to purchase ordinary shares;
|
| - |
Promissory Notes. |
| a. |
Transactions:
|
|
Nine
months ended
September
30, |
Three
months ended
September
30 |
|||||||||||||||
|
2024
|
2023
|
2024
|
2023 | |||||||||||||
|
Share-based
compensation included in research and development expenses |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Share-based
compensation included in general and administrative expenses |
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Financial expenses
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||
| b. |
Balances:
|
|
September 30,
2024 |
December 31,
2023 |
|||||||
|
Non-Current
liabilities - |
||||||||
|
Warrants
to purchase preferred shares |
$
|
|
$
|
|
||||
|
Private
warrants to purchase ordinary shares |
$
|
|
|
|||||
|
Promissory
Note |
$
|
|
$
|
|
||||
| a. |
On October 1, 2024, the Company completed an equity
raise through the ELOC, issuing
|
| b. |
On October 22, 2024, the Company completed an
equity raise through the ELOC, issuing
|
| c. |
On October 29, 2024, the Company received a deficiency
letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying
the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company’s Ordinary Shares
was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market. |
| d. |
d. For information regarding the reverse share
split, see Note 1 (g) |
|
Page | |
|
F-67 | |
|
CONSOLIDATED
FINANCIAL STATEMENTS: |
|
| F-68 - F-69 | |
| F-70 | |
|
F-71 | |
| F-72 - F-73 | |
| F-74 - F-99 |

|
/s/Kesselman & Kesselman |
|
|
Certified Public Accountants (lsr.) |
|
|
A member firm of PricewaterhouseCoopers International Limited | |
|
Tel-Aviv, Israel |
|
|
May 9, 2024, except for the effects of the reverse share split
discussed in note 1c, and except for the effects of the merger exchange ratio discussed in note 1c, as to which the date is January 13,
2025 | |
|
Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103,
Israel,
P.O Box 50005 Tel-Aviv 6150001, Telephone: +972 -3- 7954555, Fax:+972
-3- 7954556, www.pwc.com/il |
|
December
31 |
||||||||
|
2023
|
2022
|
|||||||
|
Assets
|
||||||||
|
CURRENT
ASSETS: |
||||||||
|
Cash
and cash equivalents |
$
|
|
$
|
|
||||
|
Restricted
cash |
|
|
||||||
|
Short
term deposits |
|
|
||||||
|
Prepaid
expenses |
|
|
||||||
|
Other
current assets |
|
|
||||||
|
TOTAL
CURRENT ASSETS |
|
|
||||||
|
NON-CURRENT
ASSETS: |
||||||||
|
Restricted
cash |
|
|
||||||
|
Long-term
deposit |
|
|
||||||
|
Property
and equipment, net |
|
|
||||||
|
Operating
lease right-of-use asset |
|
|
||||||
|
TOTAL
NON-CURRENT ASSETS |
|
|
||||||
|
TOTAL
ASSETS |
$
|
|
$
|
|
||||
|
December
31 |
||||||||
|
2023
|
2022
|
|||||||
|
Liabilities
and redeemable convertible preferred shares, net of capital deficiency |
||||||||
|
CURRENT
LIABILITIES: |
||||||||
|
Trade
payables |
$
|
|
$
|
|
||||
|
Current
maturities of operating lease liability |
|
|
||||||
|
Warrants
to preferred shares (including $ |
|
|
||||||
|
Employee
related obligations |
|
|
||||||
|
Accrued
expenses |
|
|
||||||
|
TOTAL
CURRENT LIABILITIES |
|
|
||||||
|
NON-CURRENT
LIABILITIES: |
||||||||
|
Long-term
operating lease liability |
|
|
||||||
|
TOTAL
NON-CURRENT LIABILITIES |
$
|
|
$
|
|
||||
|
TOTAL
LIABILITIES |
$
|
|
$
|
|
||||
|
COMMITMENTS
AND CONTINGENT LIABILITIES (Note 6) |
||||||||
|
REDEEMABLE
CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS: |
||||||||
|
Convertible
Series A Preferred Shares (NIS |
||||||||
|
Convertible
Series A-1 Preferred Shares (NIS |
||||||||
|
Convertible
Series A-2 Preferred Shares (NIS |
||||||||
|
Convertible
Series A-3 Preferred Shares (NIS |
||||||||
|
Convertible
Series A-4 Preferred Shares (NIS |
||||||||
|
TOTAL
REDEEMABLE CONVERTIBLE PREFERRED SHARES |
|
|
||||||
|
CONTINGENTLY
REDEEMABLE NON-CONTROLLING INTERESTS |
|
|
||||||
|
TOTAL
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS |
$
|
|
$
|
|
||||
|
CAPITAL
DEFICIENCY:
Ordinary
shares (($ |
|
|
||||||
|
Additional
paid-in capital |
|
|
||||||
|
Accumulated
deficit |
(
|
)
|
(
|
)
| ||||
|
TOTAL
CAPITAL DEFICIENCY |
$
|
(
|
)
|
$
|
(
|
)
| ||
|
TOTAL
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
|
$
|
|
$
|
|
||||
|
TOTAL
LIABILITIES, REDEEMABLE CONVERTIBLE
PREFERRED
SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY |
$
|
|
$
|
|
||||
|
Year ended December 31
|
||||||||
|
2023 |
2022 |
|||||||
|
OPERATING EXPENSES: |
||||||||
|
Research and development,
net (including $ |
$ |
|
$ |
|
||||
|
General and administrative
(including $ |
|
|
||||||
|
TOTAL OPERATING EXPENSES |
|
|
||||||
|
OPERATING LOSS |
|
|
||||||
|
Financial expenses (income), net (including $ |
|
(
|
) | |||||
|
LOSS BEFORE INCOME TAX |
$ |
|
$ |
|
||||
|
INCOME TAX |
|
|
||||||
|
NET LOSS FOR THE YEAR |
$ |
|
$ |
|
||||
|
Attributable to: |
||||||||
|
Equity holders of the Company |
|
|
||||||
|
Non-controlling interests |
|
|
||||||
|
$ |
|
$ |
|
|||||
|
LOSS PER SHARE, BASIC AND DILUTED |
$ |
|
$ |
|
||||
|
WEIGHTED
AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE |
|
|
||||||
F-70
SILEXION THERAPEUTICS CORP
CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S. dollars in thousands, except per share data)
| Redeemable Convertible Preferred Shares |
Ordinary shares |
Additional paid-in Capital |
Accumulated deficit |
Total
capital deficiency |
Total redeemable non- controlling interests, net of capital deficiency |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Series A preferred shares |
Series A-1 preferred shares |
Series A-2 preferred shares |
Series A-3 preferred shares |
Series A-4 preferred shares |
Contingently redeemable non- controlling interests |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BALANCE AT JANUARY 1, 2022 | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CHANGES DURING 2022: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Preferred A-2 shares, net of issuance cost, see Note 9(b) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of simple agreements for future equity (SAFE) to Preferred A-3 shares, see Note 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BALANCE AT DECEMBER 31, 2022 | $ | $ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CHANGES DURING 2023: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Preferred A-4 shares, net of issuance cost, see Note 9(b) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BALANCE AT DECEMBER 31, 2023 | $ | $ | $ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| * Represents an amount less than $1 |
The accompanying notes are an integral part of these consolidated financial statements.
F-71
|
Year
ended December 31 |
||||||||
|
2023
|
2022
|
|||||||
|
CASH
FLOWS FROM OPERATING ACTIVITIES: |
||||||||
|
Net
loss |
$
|
(
|
)
|
$
|
(
|
)
| ||
|
Adjustments
required to reconcile loss to net cash used in operating activities: |
||||||||
|
Depreciation
|
|
|
||||||
|
Share-based
compensation expenses |
|
|
||||||
|
Non-cash
financial expenses |
|
(
|
)
| |||||
|
Gain
on disposal of property and equipment |
(
|
)
|
|
|||||
|
Changes
in operating assets and liabilities: |
||||||||
|
Increase
(decrease) in prepaid expenses |
(
|
)
|
|
|||||
|
Increase
(decrease) in other receivables |
|
(
|
)
| |||||
|
Increase
(decrease) in trade payable |
|
(
|
)
| |||||
|
Net
change in operating lease |
|
(
|
)
| |||||
|
Increase
(decrease) in employee related obligations |
(
|
)
|
(
|
)
| ||||
|
Increase
(decrease) in accrued expenses |
|
(
|
)
| |||||
|
Net
cash used in operating activities |
(
|
)
|
(
|
)
| ||||
|
CASH
FLOWS FROM INVESTING ACTIVITIES: |
||||||||
|
Proceeds
from long-term deposits |
|
|
||||||
|
Investment
in short-term deposit |
|
(
|
)
| |||||
|
Proceeds
from short-term deposit |
|
|
||||||
|
Purchase
of property and equipment |
(
|
)
|
(
|
)
| ||||
|
Proceeds
from sale of property and equipment |
|
|
||||||
|
Net
cash provided by (used in (investing activities |
|
(
|
)
| |||||
|
CASH
FLOWS FROM FINANCING ACTIVITIES: |
||||||||
|
Proceeds
from issuance of preferred shares and warrants, net of issuance costs |
|
|
||||||
|
Exercise
of options |
|
|
||||||
|
Net
cash provided by financing activities |
|
|
||||||
|
DECREASE
IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH |
(
|
)
|
(
|
)
| ||||
|
EXCHANGE
RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH |
(
|
)
|
(
|
)
| ||||
|
BALANCE
OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR |
|
|
||||||
|
BALANCE
OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR |
$
|
|
$
|
|
||||
|
Year
ended December 31 |
||||||||
|
2023
|
2022 | |||||||
|
Appendix
A – RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN
THE CONSOLIDATED BALANCE SHEETS: |
||||||||
|
Cash
and cash equivalents |
|
|
||||||
|
Restricted
cash |
|
|
||||||
|
TOTAL
CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS |
$
|
|
$
|
|
||||
|
Appendix
B - SUPPLEMENTARY INFORMATION:
|
||||||||
|
SUPPLEMENTARY
INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: |
||||||||
|
Transition
to ASC 842 - recognition of operating right of use assets and operating lease liabilities |
$
|
|
$
|
|
||||
|
Conversion
of SAFEs to preferred shares and warrants |
$
|
|
$
|
|
||||
|
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||
|
Interest
received |
$
|
|
$
|
|
||||
| a. |
Silexion
Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated in Israel and began its operations
on November 30, 2008. Since its incorporation, the Company has been engaged in |
| b. |
On
April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (GIBF) to establish a new company in
China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter - the "Subsidiary"). The Company
owns |
| c. |
On
April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter, “A&R BCA”)
with Moringa acquisition Corp (the “SPAC“), Biomotion Sciences, August M.S. Ltd. and Moringa Acquisition Merger Sub Corp (hereinafter
- the “Business Combination”) which replaced an earlier business combination agreement, for further information see Note
15(a) and (b). Subsequently, Biomotion Sciences changed its name to Silexion Therapeutics Corp (“New Silexion”).
|
| d. |
In
October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign
against Hamas and other terrorist organizations. |
F-74
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| e. |
Going
concern: |
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of presentation |
The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).
| b. | Use of estimates |
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to fair value of financial instruments and share-based compensation see Notes 12 and 11, respectively.
| c. | Functional currency |
The Company’s operations are currently conducted in Israel and some of the Company’s expenses are currently paid in new Israeli shekels (“NIS”); however, the markets for the Company’s future products are located outside of Israel. Financing activities are conducted in U.S. dollar (“dollar” or “$”). The Company’s management believes that the US dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the dollar. The functional currency of the Subsidiary is U.S. dollar, inter alia, in light of the composition of expenses and expected volume of intercompany transactions with the Company.
F-75
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions — exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) — historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.
| d. | Principles of consolidation |
The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
The financial statements of the Company and of the Subsidiary are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group.
| e. | Cash and cash equivalents |
The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.
Bank balances for which use by the Company is subject to third party contractual restrictions are included as part of cash unless the restrictions result in a bank balance no longer meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12 months after the end of the reporting period, the related amounts are classified as non-current in Balance sheets.
| f. | Restricted cash |
As
of December 31, 2023 and 2022, the Company pledged an amount of $
The
Company is required to hold a minimum amount of NIS
| g. | Property and equipment: |
Property and equipment are stated at cost, net of accumulated depreciation.
Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:
| % | ||||
| Computers and software | ||||
| Laboratory and electronic equipment | ||||
| Leasehold improvements* | ||||
F-76
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
|
* |
Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements. |
| h. | Employee rights upon retirement |
The Company is required to make severance payments upon dismissal of an employee or upon termination of employment in certain circumstances.
In
accordance with the current employment terms with all of its employees located in Israel, and pursuant to Section 14 of the Israeli
Severance Pay Law, 1963, the Company makes and has been continuously making, since the beginning of employment of each of its current
employees, regular deposits, at a rate of
Under these circumstances, the Company is currently relieved from any severance pay liability with respect to each such employee. Neither the liability in respect of these employees nor the credit for the amounts funded are reflected on the Company’s consolidated balance sheets, as the amounts funded are not under the control or management of the Company and the severance pay risks have been irrevocably transferred to the applicable insurance companies.
The
amounts of severance payment expenses were $
| i. | Fair value measurement |
Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
| Level 1: | Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. | |
| Level 2: | Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities. | |
| Level 3: | Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. |
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
| j. | Financial instruments issued |
When the Company issues preferred shares, it first considers the provisions of ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) in order to determine whether the preferred share should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes the instrument’s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company’s redeemable convertible preferred shares are not mandatorily or currently redeemable. However, they include clauses that could constitute as in-substance redemption clauses that are outside of the Company’s control. As such, all shares of redeemable convertible preferred shares have been presented outside of permanent equity.
F-77
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
When the Company issues other freestanding instruments, the Company first analyzes the provisions of ASC 480 in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-40 in order to determine whether the instrument should be classified within equity or classified as an asset or liability, with subsequent changes in fair value recognized in the statements of operations in each period.
The Company’s issued financial instruments convertible to preferred shares are in the scope of ASC 480. For further details see Note 7 and Note 8.
| k. | Redeemable Non-controlling Interest |
Non-controlling interests with embedded redemption features, whose settlement is not at the Company’s discretion, are considered redeemable non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the Company’s consolidated balance sheets. Redeemable non-controlling interests are measured at the greater of the initial carrying amount adjusted for the non-controlling interest’s share of comprehensive income or loss or its redemption value. Subsequent adjustment of the amount presented in temporary equity is currently not required because the Company’s management estimates that it is not probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded through additional paid-in capital.
| l. | Research and development expenses |
Research and development costs are charged to the statements of operations as incurred. Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of payroll and subcontractors, as well as share-based payments. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are used or the services are rendered.
Grants received from the Israeli Innovation Authority (“IIA”) for approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and included as a deduction from research and development expenses, see Note 5(a). The Company did not receive any grants during 2022 and 2023.
| m. | Share-based compensation |
The Company’s employees and non-employees share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period using the straight-line method.
The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. Forfeitures are recognized as they occur.
The Company accounts for its non-employees’ equity-classified share-based payment in a similar manner.
F-78
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| n. | Leases |
The
Company adopted the ASC 842, Leases accounting guidance. The Company recognized new right-of-use assets and operating lease liabilities
of $
The Company recognizes operating lease payments in the consolidated statements of operations on a straight-line basis over the lease term. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts representing the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The discount rate for the lease is the rate in the lease unless that rate cannot readily determined. As the Company’s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (“IBR”) based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The lease agreement included an option to extend or terminate the lease. The Company exercised its option to extend the lease period up to July 2025.
Payments under the Company’s lease arrangements are primarily fixed, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease right-of-use assets and liabilities. The Company elected the practical expedient not to separate lease and non-lease components.
| o. | Loss per share |
The
Company calculates loss per share using the two-class method required for participating securities. This method entails allocating income
available to ordinary shareholders for the period between ordinary shares and participating securities based on their respective rights
to receive dividends as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss by the
weighted average number of shares of Ordinary shares outstanding during the year, and fully vested pre-funded options for the Company's
Ordinary shares at an exercise price of $
| p. | Income taxes: |
| 1) | Deferred taxes |
Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Given the Company’s losses, the Company has provided a full valuation allowance with respect to its deferred tax assets.
F-79
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| 2) | Uncertainty in income tax |
The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement.
| q. | Concentration of credit risks |
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.
| r. | Operating segments and geographical information: |
The Company is managed as one R&D department during its startup phase that has yet to earn revenues. The Company’s Chief Executive Office (“CEO”) was identified as the chief operating decision maker (“CODM”). The CODM reviews the financial information every quarter. Accordingly, the company had determined to operate under one reportable segment.
All of the Company long-lived assets are located in Israel.
| s. | New accounting pronouncements: |
The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act for EGCs, the Company has elected to defer compliance with new or revised ASUs until it is required to comply with such updates, which is generally consistent with the adoption dates of private companies.
Recently Adopted accounting pronouncements:
In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, which replaces the existing incurred loss model with a current expected credit loss (“CECL”) model that requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. Under the ASU, the Company is required to use a forward-looking CECL model for accounts receivables and other financial instruments. The Company adopted the ASU on January 1, 2023 and it did not have a material impact on its consolidated financial statement.
Recently issued accounting standards not yet adopted:
| 1) |
In June 2022, the FASB issued ASU 2022-03 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring
|
F-80
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| 2) |
its fair value. The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The ASU also introduces new disclosure requirements for equity securities subject to contractual sale restrictions. As an Emerging Growth Company, the ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the effect that ASU 2022-03 will have on its consolidated financial statements and related disclosures. |
| 3) |
In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU also require that a public entity that has a single reportable segment to provide all the disclosures required by the amendments and all existing segment disclosures in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating this ASU to determine its impact on the Company's segment disclosures. | |
| 4) |
In December, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of adoption. |
F-81
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 3 - PROPERTY AND EQUIPMENT, NET:
Composition of property and equipment, grouped by major classifications, is as follows:
| December 31 | ||||||||
| 2023 | 2022 | |||||||
| Cost: | ||||||||
| Computers |
$ |
|
$ |
|
||||
| Laboratory and electronic equipment | ||||||||
| Office furniture | ||||||||
| Communication equipment | ||||||||
| Leasehold improvements | ||||||||
| $ | $ | |||||||
| Accumulated depreciation: | ||||||||
| Computers | ||||||||
| Laboratory and electronic equipment | ||||||||
| Office furniture | ||||||||
| Communication equipment | ||||||||
| Leasehold improvements | ||||||||
| $ | $ | |||||||
| Property and equipment, net | $ | $ | ||||||
Depreciation expenses were $
NOTE 4 - LEASES:
The Company leases offices for its facilities in Israel by way of an operating lease. The lease agreement for such offices is denominated in NIS and linked to the Israeli consumer price index (“CPI”).
The
Company provided the lessor with a bank guarantee as a rental security. The bank in turn placed a pledge over restricted cash of $
The
lease for the offices expires on July 31, 2025. The remaining lease term is up to
Operating lease costs for the years ended December 31, 2022 and 2023 are as follows:
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Fixed payments and variable payments that depend on an index or rate: | ||||||||
| Office and operational lease expenses | $ | $ | ||||||
| Variable lease cost (included in the operating lease costs) | $ | $ | ||||||
| Total operating lease costs | $ | $ | ||||||
Operating cash flows, for amounts included in the measurement of lease liabilities, are as follows:
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Office and operational spaces lease expenses | $ | $ | ||||||
F-82
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 4 - LEASES (continued):
Supplemental information related to operating leases is as follows:
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating lease right-of-use assets | $ | $ | ||||||
| Operating lease liabilities | $ | $ | ||||||
| Weighted average remaining lease term (years) | ||||||||
| Weighted average discount rate | % | % | ||||||
As of December 31, 2023, the Company has not entered into lease agreements that include options to extend them that are not included in the measurement of the lease liability.
The following table outlines maturities of the Company’s operating lease liabilities as of December 31, 2023:
|
Operating lease liabilities |
||||
| 2024 | $ | |||
| 2025 | ||||
| Total undiscounted lease payments | $ | |||
| Less – imputed interest | $ | |||
| Present value of lease liabilities | $ | |||
| a. |
Research
and development expenses, net: |
|
Year ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Payroll
and related expenses |
$
|
|
$
|
|
||||
|
Subcontractors
and consultants |
|
|
||||||
|
Materials
|
|
|
||||||
|
Rent and
maintenance |
|
|
||||||
|
Travel expenses
|
|
|
||||||
|
Other
|
|
|
||||||
|
$
|
|
$
|
|
|||||
| b. |
General
and administrative expenses: |
|
Payroll
and related expenses |
$
|
|
$
|
|
||||
|
Professional
services |
|
|
||||||
|
Depreciation
|
|
|
||||||
|
Rent and
maintenance |
|
|
||||||
|
Patent registration
|
|
|
||||||
|
Travel expenses
|
|
|
||||||
|
Other
|
|
|
||||||
|
$
|
|
$
|
|
F-83
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| c. |
Financial
expense, net: |
|
Change
in fair value of financial liabilities measured at fair value |
$
|
|
$
|
(
|
)
| |||
|
Issuance
costs |
|
|
||||||
|
Interest
income |
(
|
)
|
(
|
)
| ||||
|
Foreign
currency exchange loss, net |
|
|
||||||
|
Other
|
|
|
||||||
|
Total
financial expense (income), net |
$
|
|
$
|
(
|
) |
NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES:
During 2009 to 2020, the Company received
several approvals from the IIA for participation in research and development activities performed by the Company (“Support Grants”)
in a total amount of $
The Company is obligated to pay royalties
to the IIA amounting to
As of December 31, 2023, the total
royalty amount that may be payable by the Company is approximately $
F-84
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 8 - WARRANTS TO PURCHASE PREFERRED SHARES:
| a. |
In
connection with the Series A-2 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire |
| b. |
Concerning
the Series A-4 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire |
The Company
classified the warrants for the purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance
sheets, as these warrants were freestanding financial instruments which underlying shares are contingently redeemable and, therefore,
may obligate the Company to transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon
the date of issuance and was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income)
amounting to $(
For further information in respect of warrants issuance to service provider see Note 11(1).
| a. |
As
of December 31, 2023 and 2022, the share capital is composed of 0.09 NIS par value shares, as follows: |
|
December
31, 2023 |
||||||||||||||||
|
Authorized
|
Issued
and paid |
Carrying
Value
|
Liquidation
Preference
|
|||||||||||||
|
Ordinary
Shares |
|
|
$
|
|
||||||||||||
|
Preferred
A Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-1 Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-2 Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-3 Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-4 Shares |
|
|
$
|
|
$
|
|
||||||||||
|
December
31, 2022 |
||||||||||||||||
|
Authorized
|
Issued
and paid |
Carrying
Value
|
Liquidation
Preference
|
|||||||||||||
|
Ordinary
Shares |
|
|
$
|
|
||||||||||||
|
Preferred
A Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-1 Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-2 Shares |
|
|
$
|
|
$
|
|
||||||||||
|
Preferred
A-3 Shares |
|
|
$
|
|
$
|
|
||||||||||
F-85
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| b. |
Issuance
of shares: |
| 1) |
On
January 14, 2022, the Company signed an agreement to issue shares in consideration for an investment in the amount of $
|
| 2) |
On
May 30, 2023, the Company entered into an agreement to receive an investment in a total amount of $
|
| c. |
Shareholders
rights: |
| 1) |
The
Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share
in the distribution of dividends, if any declared by the Company. |
| a) |
Distribution
Preference |
F-86
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| b) |
Liquidation
Preference: |
| c) |
Dividend
Preference: |
F-87
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| d) |
Conversion
Rights: |
| d. |
Silenseed
China Minority Equityholder Rights: |
| a. |
Conversion
("Put/Call") Option: Either GIBF or the Company may elect that the equity rights of GIBF in the Subsidiary shall be exchanged for the
most senior shares (i.e., preferred shares) of the Company, consequently turning the Subsidiary into a wholly-owned subsidiary of the
Company. The number of shares to be issued to GIBF upon such exchange shall be calculated by converting the total cash amount invested
by GIBF in the Subsidiary (the "Contribution Amount"), into the most senior class of shares of the Company as of May 30, 2023, based on
a pre-money valuation of the Company of US$
|
| b. |
"Company
Exit Event" means the consummation of: (i) an initial public offering of Company, in a stock exchange, directly or via a SPAC (or similar
methods); (ii) the sale of all or substantially all of the securities or assets of the Company (or an exclusive license with respect to
all or substantially all of the assets of Company); (iii) a merger or acquisition of the Company (following which existing shareholders
as of immediately prior to such transaction hold less than |
F-88
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| 1) |
Anti-Dilution
Protection: If the Subsidiary issues any additional equity rights in the Subsidiary to a third-party investor in the next two equity
investment rounds of the Subsidiary, reflecting a purchase price per equity right lower than the purchase price per equity right paid
by GIBF, GIBF will be issued additional equity rights of the Subsidiary for no consideration, based on a broad based weighted average
formula. |
| 2) |
Registration
Rights: GIBF shall be entitled to the same rights to register its equity rights in the Subsidiary as part of an IPO of the Subsidiary,
as granted to Company, on a pro-rata basis. |
| 3) |
Liquidation
Preference: In the event of an IPO in which the Subsidiary's valuation is at least $ |
| 4) |
Other
rights, such as right of first refusal for GIBF to purchase the Company’s equity rights in the Subsidiary if the Company proposes
to sell or receives an offer to sell its equity rights; a right of co-sale for GIBF to participate in a proposed sale of the Company’s
equity rights in the Subsidiary on a pro-rata basis; a preemptive right for both investors to participate in the issuance of new securities
by the Subsidiary until the consummation of an IPO or an Exit Event (as defined in the Subsidiary’s Articles).
|
NOTE 10 - INCOME TAXES:
| a. |
Corporate
taxation in Israel |
| b. |
Income
taxes on non-Israeli subsidiary |
| c. |
Tax
loss carryforwards |
F-89
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Israel
|
$
|
|
$
|
|
||||
|
Subsidiary
outside of Israel |
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
| d. |
Uncertainty
in income tax |
| e. |
Tax
rate reconciliation |
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Loss
before income taxes |
$
|
(
|
)
|
$
|
(
|
)
| ||
|
Statutory
tax rate |
|
%
|
|
%
| ||||
|
Computed
“expected” tax income |
(
|
)
|
(
|
)
| ||||
|
Exchange
rate differences |
|
|
||||||
|
Non-deductible
share-based compensation |
|
|
||||||
|
Non-deductible
financial instruments valuation |
|
(
|
)
| |||||
|
Effect
of other non-deductible differences |
|
|
||||||
|
Change
in valuation allowance |
|
|
||||||
|
Subsidiary
tax rate differences |
(
|
)
|
(
|
)
| ||||
|
Reported
taxes on income |
$
|
|
$
|
|
||||
F-90
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| f. |
Deferred
tax |
|
December
31 |
||||||||
|
2023
|
2022
|
|||||||
|
Deferred
tax assets |
||||||||
|
Operating
loss carryforwards |
$
|
|
|
|||||
|
Research
and development |
|
|
||||||
|
Accrued
expenses |
|
|
||||||
|
Lease
liability |
|
|
||||||
|
Other
|
|
|
||||||
|
Total
deferred tax assets |
$
|
|
$
|
|
||||
|
Deferred
tax liabilities |
||||||||
|
Right
of use asset |
(
|
)
|
(
|
)
| ||||
|
Total
deferred tax liabilities |
$
|
(
|
)
|
$
|
(
|
)
| ||
|
Valuation
allowance |
$
|
(
|
)
|
$
|
(
|
)
| ||
|
Deferred
tax assets, net of valuation allowance |
$
|
|
$
|
|
||||
| g. |
Roll
forward of valuation allowance: |
|
Balance
as of December 31, 2021 |
$
|
(
|
)
| |
|
Additions
|
(
|
)
| ||
|
Balance
as of December 31, 2022 |
$
|
(
|
)
| |
|
Additions
|
(
|
)
| ||
|
Balance
as of December 31, 2023 |
$
|
(
|
)
|
| h. |
Income
tax assessments |
F-91
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| 1) |
Warrants
to service provider |
| 2) |
Employee
Stock Option Plan |
F-92
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 11 - SHARE-BASED COMPENSATION (continued):
|
Number
of options |
Weighted-average
exercise price (in U.S. dollars) |
Weighted-
average remaining contractual term
(in
years) |
Aggregate
intrinsic
value
|
|||||||||||||
|
Outstanding
at December 31, 2022 |
|
$
|
|
|
$
|
|
||||||||||
|
Granted
|
|
$
|
|
|
$
|
-
|
||||||||||
|
Exercised
|
|
$
|
|
|
$
|
-
|
||||||||||
|
Forfeited
|
|
$
|
|
|
$
|
-
|
||||||||||
|
Expired
|
(
|
)
|
$
|
(
|
)
|
|
$
|
-
|
||||||||
|
Outstanding
at December 31, 2023 |
|
$
|
|
|
$
|
|
||||||||||
|
Exercisable
at December 31, 2023 |
|
$
|
|
|
$
|
|
||||||||||
|
Vested
and expected to vest at December 31, 2023 |
|
$
|
|
|
$
|
|
||||||||||
|
Number
of options |
Weighted-average
exercise price (in U.S. dollars) |
Weighted-
average remaining contractual term
(in
years) |
Aggregate
intrinsic
value
|
|||||||||||||
|
Outstanding
at December 31, 2021 |
|
$
|
|
|
$
|
|
||||||||||
|
Granted
|
|
$
|
|
|
$
|
-
|
||||||||||
|
Exercised
|
(
|
)
|
$
|
|
(
|
)
|
$
|
-
|
||||||||
|
Forfeited
|
(
|
)
|
$
|
|
(
|
)
|
$
|
-
|
||||||||
|
Expired
|
(
|
)
|
$
|
(
|
)
|
|
$
|
-
|
||||||||
|
Outstanding
at December 31, 2022 |
|
$
|
|
|
$
|
|
||||||||||
|
Exercisable
at December 31, 2022 |
|
$
|
|
|
$
|
|
||||||||||
|
Vested
and expected to vest at December 31, 2022 |
|
$
|
|
|
$
|
|
||||||||||
F-93
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 11 - SHARE-BASED COMPENSATION (continued):
|
Year ended
December 31, 2022
|
|||
|
Employees
|
|||
|
Expected
term (in years) |
|
||
|
Expected
volatility |
|
| |
|
Risk-free
interest rate |
|
| |
|
Expected
dividend yield |
|
||
|
Exercise
price |
$
|
||
|
Non-Employees
|
|||
|
Expected
term (in years) |
|
||
|
Expected
volatility |
|
| |
|
Risk-free
interest rate |
|
| |
|
Expected
dividend yield |
|
| |
|
Exercise
price |
$
|
|
Year
ended December 31, 2022 | ||||||||||
|
Award
amount |
Exercise
price |
Vesting
period |
Expiration
| |||||||
|
Employees
|
|
|
|
| ||||||
|
Non-employees
|
|
|
|
| ||||||
|
Total
granted |
|
|||||||||
F-94
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 11 - SHARE-BASED COMPENSATION (continued):
|
Number
of
options
|
Weighted-average
grant-date fair
value
price |
|||||||
|
Outstanding
at December 31, 2022 |
|
$
|
|
|||||
|
Granted
|
|
$
|
|
|||||
|
Vested
|
(
|
)
|
$
|
|
||||
|
Forfeited
|
|
$
|
|
|||||
|
Outstanding
at December 31, 2023 |
|
$
|
|
|||||
|
Outstanding
at December 31, 2021 |
|
$
|
|
|||||
|
Granted
|
|
$
|
|
|||||
|
Vested
|
(
|
)
|
$
|
|
||||
|
Forfeited
|
(
|
)
|
$
|
|
||||
|
Outstanding
at December 31, 2022 |
|
$
|
|
|||||
|
Number
of
options
|
Weighted-average
grant-date fair
value
price |
|||||||
|
Outstanding
at December 31, 2022 |
|
$
|
|
|||||
|
Granted
|
|
$
|
|
|||||
|
Vested
|
(
|
)
|
$
|
|
||||
|
Forfeited
|
|
$
|
|
|||||
|
Outstanding
at December 31, 2023 |
|
$
|
|
|||||
|
Outstanding
at December 31, 2021 |
|
$
|
|
|||||
|
Granted
|
|
$
|
|
|||||
|
Vested
|
(
|
)
|
$
|
|
||||
|
Forfeited
|
|
$
|
|
|||||
|
Outstanding
at December 31, 2022 |
|
$
|
|
|||||
F-95
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 11 - SHARE-BASED COMPENSATION (continued):
The share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:
| Year ended December 31 | ||||||||
| 2023 | 2022 | |||||||
| Research and development | $ | $ | ||||||
| General and administrative | ||||||||
| $ | $ | |||||||
NOTE 12 - FAIR VALUE MEASUREMENTS:
|
December
31, 2023 |
||||||||
|
Level
3 |
Total
|
|||||||
|
Financial
Liabilities |
||||||||
|
Warrants
to preferred shares |
$
|
|
$
|
|
||||
|
December
31, 2022 |
||||||||
|
Level
3 |
Total
|
|||||||
|
Financial
Liabilities |
||||||||
|
Warrants
to preferred shares |
$
|
|
$
|
|
||||
|
2023
|
2022
|
|||||||||||
|
Warrants
|
Warrants
|
SAFE
|
||||||||||
|
Fair value
at the beginning of the year |
$
|
|
$
|
|
$
|
|
||||||
|
Issuance
|
|
|
|
|||||||||
|
Change in
fair value |
|
(
|
)
|
|
||||||||
|
Conversion
to equity |
|
|
(
|
) | ||||||||
|
Fair value
at the end of the year |
$
|
|
$
|
|
$
|
|
||||||
F-96
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
|
December
31 |
||||||||
|
|
2023
|
2022
|
||||||
|
Expected
volatility |
|
%
|
|
%
| ||||
|
Assumptions
regarding the price of the underlying shares: |
||||||||
|
Probability
of an IPO scenario (including de-SPAC transaction) |
|
%
|
|
|||||
|
Expected
time to IPO (including de-SPAC transaction) (years) |
|
|
||||||
|
Probability
of other liquidation events |
|
%
|
|
%
| ||||
|
Expected
time to liquidation (years) |
|
|
||||||
|
Expected
return on Equity |
|
%
|
|
%
| ||||
NOTE 13 - NET LOSS PER SHARE:
|
Year
ended December 31 |
||||||||
|
2023
|
2022
|
|||||||
|
Numerator:
|
||||||||
|
Net
loss for the year |
$
|
|
$
|
|
||||
|
Net
loss attributable to ordinary shareholders, basic and diluted: |
$
|
|
$
|
|
||||
|
Denominator:
|
||||||||
|
Weighted-average
shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted |
|
|
||||||
|
Net
loss per share attributable to ordinary shareholders, basic and diluted |
$
|
|
$
|
|
||||
F-97
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
| - |
Redeemable
convertible preferred shares (see Note 9); |
| - |
Warrants
to purchase redeemable convertible preferred shares (see Note 8); |
| - |
Simple
agreements for future equity (see Note 7); |
| - |
Share-based
compensation issuable at substantial consideration (see Note 11). |
NOTE 14 - TRANSACTIONS AND BALANCES WITH RELATED PARTIES:
| a. |
Transactions:
|
|
Year
ended December 31 |
||||||||
|
2023
|
2022
|
|||||||
|
Share-based
compensation included in research and development expenses |
$
|
|
$
|
|
||||
|
Share-based
compensation included in general and administrative expenses |
$
|
|
$
|
|
||||
|
Financial
expenses |
$
|
|
$
|
|
||||
| b. |
Balances:
|
|
December
31 |
||||||||
|
2023
|
2022
|
|||||||
|
Non-Current
liabilities — |
||||||||
|
Warrants
to preferred shares |
$
|
|
$
|
|
||||
NOTE 15 - SUBSEQUENT EVENT:
The Company’s management has performed an evaluation of subsequent events through May 09th, 2024, the date the financial statements were available to be issued.
| a. | On February 21, 2024, the Company entered into a business combination agreement with Moringa Acquisition Corp. (the “SPAC”), an exempted company incorporated under the Laws of the Cayman Islands whose class A ordinary shares (as well as other instruments) are listed for trade on the Nasdaq Global Market (NASDAQ:MACA), and April.M.G. Ltd. (the “April Merger Sub”), a limited liability company organized under the laws of the State of Israel and a wholly-owned subsidiary of the SPAC (the “Original BCA”). According to the Original BCA, April Merger Sub would merge with and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC continuing as a public company following the completion of the merger and with its securities continuing to be traded on Nasdaq. |
F-98
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S. DOLLARS IN THOUSANDS
NOTE 15 - SUBSEQUENT EVENT (continued):
| b. | On April 3, 2024, the SPAC and the Company restructured the transactions contemplated under the Original BCA by entering into the A&R BCA by and among Biomotion Sciences, a Cayman Islands exempted company (the “New Pubco”), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Pubco (the “Merger Sub 1”), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Pubco (the “Merger Sub 2”), the SPAC and the Company. The A&R BCA amends and restates, in its entirety, the Original BCA. |
Pursuant to the A&R BCA, Merger Sub 2 will merge with and into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the “SPAC Merger”), and Merger Sub 1 will merge with and into the Company, with the Company continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the “Acquisition Merger”).
Upon
the effectiveness of the SPAC Merger, each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary
share will convert into an ordinary share of New Pubco on a one-for-one basis, and each outstanding warrant to purchase
Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of the Company will convert into such
number of ordinary shares of New Pubco as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $
The completion of the A&R BCA is subject to the satisfaction of certain conditions, including obtaining the consent of the shareholders of each of the SPAC and the Company and the declaration of effectiveness of a registration statement on form S-4 by the U.S. Securities and Exchange Commission in relation to issuance of New Pubco ordinary shares to be issued or issuable to the SPAC’s and the Company’s respective security holders pursuant to the A&R BCA. To facilitate the A&R BCA, the parties further entered into certain ancillary agreements.
The A&R BCA further imposes various restrictions on the total liabilities which the SPAC may incur prior to closing, including the total indebtedness toward the sponsor of the SPAC, and the terms on which such indebtedness will be repaid or converted, whereas such conversion, if and when it occurs, will further dilute the holdings of all shareholders of New Pubco at that time, including the former shareholders of the Company.
| c. |
For information regarding the reverse share split, see Note 1 (c) |
F-99
Silexion Therapeutics Corp
|
|
Amount |
|||
|
SEC registration fee |
$ |
517 |
||
|
Accountants’ fees and expenses |
$ |
40,000 |
||
|
Legal fees and expenses |
$ |
10,000 |
||
|
Printing fees |
$ |
2,500 |
||
|
Miscellaneous |
$ |
1,983 |
||
|
Total expenses |
$ |
55,000 |
||
|
Exhibit
No. |
Description | |
| 3.2 | ||
| 4.3 | ||
| 10.3.2* | ||
| 10.16 | ||
| 10.17 | ||
| 10.18 | ||
| 10.19 | ||
| 10.20 | ||
| 10.21 | ||
|
* |
Filed
herewith. |
|
† |
Certain
of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees
to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
|
# |
Indicates
management contract or compensatory plan, contract or arrangement. |
|
SILEXION THERAPEUTICS CORP |
| ||
|
|
|
| |
|
By: |
/s/ Ilan Hadar |
| |
|
|
Name: |
Ilan Hadar |
|
|
|
Title: |
Chairman and Chief Executive Officer |
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
/s/ Ilan Hadar |
|
Chairman and Chief Executive Officer |
|
February 12, 2025 |
|
Ilan Hadar |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
/s/ Mirit Horenshtein Hadar |
|
Chief Financial Officer and Secretary |
|
February 12, 2025 |
|
Mirit Horenshtein Hadar |
|
(Principal Financial and Accounting Officer) |
|
|
|
|
|
|
|
|
|
/s/ Dror J. Abramov |
|
Director |
|
February 12, 2025 |
|
Dror J. Abramov |
|
|
|
|
|
|
|
|
|
|
|
/s/ Ruth Alon |
|
Director |
|
February 12, 2025 |
|
Ruth Alon |
|
|
|
|
|
|
|
|
|
|
|
/s/ Ilan Levin |
|
Director |
|
February 12, 2025 |
|
Ilan Levin |
|
|
|
|
|
|
|
|
|
|
|
/s/ Avner Lushi |
|
Director |
|
February 12, 2025 |
|
Avner Lushi |
|
|
|
|
|
|
|
|
|
|
|
/s/ Shlomo Noy |
|
Director |
|
February 12, 2025 |
|
Shlomo Noy |
|
|
|
|
|
/s/ Amnon Peled |
Director |
February 12, 2025 | ||
| Amnon Peled |
|
|
PUGLISI & ASSOCIATES | |
|
|
| |
|
|
By: |
/s/ Donald J. Puglisi |
|
|
Name: |
Donald J. Puglisi |
|
|
Title: |
Authorized Representative |
![]() |
CONYERS DILL & PEARMAN LLP
SIX, 2nd Floor, Cricket Square
PO Box 2681, Grand Cayman KY1-1111
Cayman Islands
T +1 345 945 3901
conyers.com
|
|
1.
|
DOCUMENTS REVIEWED
|
| (i) |
the Registration Statement;
|
| (ii) |
the certificate of incorporation of the Company dated 2 April 2024;
|
| (iii) |
the amended and restated memorandum and articles of association of the Company adopted on 15 August 2024 (the “Articles”);
|
| (iv) |
the minutes of the meetings of the board of directors of the Company held on 15 January 2025 and 29 January 2025 (the “Resolutions”);
|
| (v) |
a Certificate of Good Standing (the “Certificate of Good Standing”)
dated 10 February 2025 issued by the Registrar of Companies in relation to the Company;
|
| (vi) |
the inducement letter dated 29 January 2025 between the Company and certain holders of existing warrants (the “Inducement Letter”) whereby such holders agreed to exercise their existing warrants to purchase an aggregate of 2,221,523 ordinary shares in the Company at the exercise price of $1.35 per
share in consideration of the Company’s agreement to issue new ordinary share purchase warrants to purchase up to an aggregate of 2,221,523 ordinary shares in the Company at an exercise price of $1.50 per share (the “New Warrants”);
|
| (vii) |
the letter agreement dated 8 September 2024 between the Company and H.C. Wainwright & Co., LLC (“Wainwright”) (the “Letter Agreement”) whereby the Company agreed to issue to Wainwright
warrants to purchase up to 155,507 ordinary shares in the Company, which have the same terms as the New Warrants except for an exercise price equal to $1.8438 per share (the “Placement Agent Warrants”);
|
| (viii) |
the form of the New Warrants;
|
| (ix) |
the form of the Placement Agent Warrants; and
|
| (x) |
such other documents and made such enquiries as to questions of law as we have deemed necessary in order to render the opinion set forth below.
|
|
2.
|
ASSUMPTIONS
|
| (a) |
the genuineness and authenticity of all signatures and the conformity to the originals of all copies (whether or not certified) examined by us and the authenticity
and completeness of the originals from which such copies were taken;
|
| (b) |
the accuracy and completeness of all factual representations made in the Registration Statement and other documents reviewed by us;
|
| (c) |
that where a document has been examined by us in draft form, it will be or has been executed in substantially the form of that draft, and where a number of drafts of
a document have been examined by us all changes thereto have been marked or otherwise drawn to our attention;
|
| (d) |
that the resolutions contained in the Resolutions were passed by unanimous resolutions of the directors of the Company at a duly convened meeting of the board of
directors of the Company, remain in full force and effect and have not been and will not be rescinded or amended;
|
| (e) |
that there is no provision of the law of any jurisdiction, other than the Cayman Islands, which would have any implication in relation to the opinions expressed
herein;
|
| (f) |
that at the time of issuance, any Registered Securities shall be issued by the Company against payment in full, which shall be equal to at least the par value
thereof, and shall be duly registered in the Company’s register of members;
|
| (g) |
that at the time of issuance, the Company will have sufficient authorised share capital to effect the issue of any Registered Securities at the time of issuance;
|
| (h) |
there are no records of the Company (other than the Resolutions), agreements, documents or arrangements other than the documents expressly referred to herein as
having been examined by us which materially affect, amend or vary the transactions envisaged in the documents expressly referred to herein or restrict the powers and authority of the directors of the Company in any way or which would affect
any opinion given herein;
|
| (i) |
the capacity, power and authority of all parties other than the Company to enter into and perform their obligations under any and all documents entered into by such
parties in connection with the issuance of the Registered Securities, and the due execution and delivery thereof by each party thereto;
|
| (j) |
the effectiveness under the laws of the United States of America of the Registration Statement and that the Registration Statement will be duly filed with and
declared effective by the Commission;
|
| (k) |
that the Registration Statement declared effective by the Commission will be in substantially the same form as that examined by us for purposes of this opinion;
|
| (l) |
that there is no provision of the law of any jurisdiction, other than the Cayman Islands, which would have any implication in relation to the opinions expressed
herein;
|
| (m) |
the legality, validity and binding effect under the laws of the State of New York (the “Foreign Laws”) of the Letter Agreement, the Inducement Letter, and the forms of the New Warrants and Placement Agent Warrants, which are expressed to be governed by the Foreign Laws, in accordance with their
respective terms;
|
| (n) |
the validity and binding effect under the Letter Agreement, the Inducement Letter, and the forms of the New Warrants and Placement Agent Warrants of the submission by
the Company to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan (the “Foreign
Courts”);
|
| (o) |
that each of the documents reviewed by us are, or will be, legal, valid, binding and enforceable against all relevant parties in accordance with their terms under all
relevant laws (other than, with respect to the Company, the laws of the Cayman Islands); and
|
| (p) |
that there is no contractual or other prohibition or restriction (other than as arising under Cayman Islands law) binding on the Company prohibiting or restricting it
from entering into and performing its obligations under the documents reviewed by us.
|
|
3.
|
QUALIFICATIONS
|
| (a) |
The term “enforceable” as used in this opinion means that an obligation is of a type which the courts of the Cayman Islands enforce. It does not mean that those
obligations will be enforced in all circumstances. In particular, the obligations of the Company in connection with any Registered Security and any indenture or other agreement or document relating thereto:
|
| (i) |
will be subject to the laws from time to time in effect relating to bankruptcy, insolvency, liquidation, possessory liens, rights of set off, reorganisation,
amalgamation, merger, consolidation, moratorium, bribery, corruption, money laundering, terrorist financing, proliferation financing or any other laws or legal procedures, whether of a similar nature or otherwise, generally affecting the
rights of creditors as well as applicable international sanctions;
|
| (ii) |
will be subject to statutory limitation of the time within which proceedings may be brought;
|
| (iii) |
will be subject to general principles of equity and, as such, specific performance and injunctive relief, being equitable remedies, may not be available;
|
| (iv) |
may not be given effect to by a Cayman Islands court if and to the extent they constitute the payment of an amount which is in the nature of a penalty; and
|
| (v) |
may not be given effect by a Cayman Islands court to the extent that they are to be performed in a jurisdiction outside the Cayman Islands and such performance would
be illegal under the laws of that jurisdiction. Notwithstanding any contractual submission to the exclusive or non-exclusive jurisdiction of specific courts, a Cayman Islands court has inherent discretion to stay or allow proceedings in
the Cayman Islands against the Company if there are other proceedings simultaneously underway against the Company in another jurisdiction.
|
| (b) |
We have made no investigation of and express no opinion in relation to the laws of any jurisdiction other than the Cayman Islands.
|
| (c) |
This opinion is to be governed by and construed in accordance with the laws of the Cayman Islands and is limited to and is given on the basis of the current law and
practice in the Cayman Islands.
|
| (d) |
This opinion is issued solely for the purposes of the filing of the Registration Statement and the offering of the Registered Securities by the Company and is not to
be relied upon in respect of any other matter.
|
|
4.
|
OPINIONS
|
| (a) |
The Company is duly incorporated and existing under the laws of the Cayman Islands and, based on the Certificate of Good Standing, is in good standing. Pursuant to
the Companies Act of the Cayman Islands (the “Act”), a company is deemed to be in good standing if all fees and penalties under the Act
have been paid and the Registrar of Companies has no knowledge that the Company is in default under the Act.
|
| (b) |
The issue of each of the Registered Securities has been duly authorised and, when issued and paid for in accordance with the form of the New Warrants or the form of
the Placement Agent Warrants, as applicable, and entered on the register of members of the Company, the Registered Securities will be validly issued, fully paid and non-assessable (which term when used herein means that no further sums are
required to be paid by the holders thereof in connection with the issue of such Registered Securities).
|
| 1. |
Amendment to Article II.
|
| (e) |
Upon the terms and subject to the conditions of this Agreement, during the Commitment Period, the Company may deliver an Accelerated Purchase Notice to the Investor, subject to satisfaction of the conditions set forth in Article VII
and otherwise provided herein. The Company shall deliver the Purchase Notice Shares, not to exceed the Accelerated Purchase Notice Limit, unless waived by Investor, underlying an Accelerated Purchase Notice as DWAC Shares to the Investor’s
Designated Brokerage Account alongside the delivery of the Accelerated Purchase Notice. An Accelerated Purchase Notice shall be deemed delivered on the Business Day that the Investor provides written consent of the acceptance of the
Accelerated Purchase Notice (the “Accelerated Purchase Notice Date”). If the Investor does not provide written consent within 15 minutes of the delivery of the Accelerated Purchase Notice, the
applicable Accelerated Purchase Notice shall be deemed void unless waived by both the Company and the Investor. Each party shall use its commercially reasonable efforts to perform or fulfill all conditions and obligations to be performed or
fulfilled by it under this Agreement so that the transactions contemplated hereby shall be consummated as soon as practicable. Each party also agrees that it shall use its commercially reasonable efforts to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective Section 2.2 of this Agreement and the transactions contemplated herein. Investor shall
not consent to accept an Accelerated Purchase Notice received less than one and a half (1.5) hours prior to the close of trading on the Principal Market, unless waived by the Investor in writing.
|
| (f) |
The Closing of an Accelerated Purchase Notice shall occur one (1) Business Day following the Accelerated Purchase Notice Date (the “Accelerated Purchase Closing Date”); whereby the Investor
shall deliver to the Company, by 5:00 p.m. New York time on the Accelerated Purchase Closing Date, the Accelerated Purchase Investment Amount by wire transfer of immediately available funds to an account designated by the Company.
|
| a. |
“Accelerated Purchase Closing Date” shall have the meaning specified in Section 2.2(f).
|
| b. |
“Accelerated Purchase Investment Amount” shall mean the applicable Purchase Notice Shares referenced in the Accelerated Purchase Notice multiplied by the applicable Accelerated Purchase
Price.
|
| c. |
“Accelerated Purchase Notice” shall mean the closing of a purchase and sale of shares of Ordinary Shares as
described in Section 2.2(e).
|
| d. |
“Accelerated Purchase Notice Date” shall have the meaning specified in Section 2.2(e).
|
| e. |
“Accelerated Purchase Notice Limit” shall mean five percent (5%) of the Average Daily Trading Volume on the Accelerated Purchase Notice Date.
|
| f. |
“Accelerated Purchase Price” shall mean the product of (i) lowest traded price of the Ordinary Shares during the Accelerated Valuation Period and (ii) ninety-nine percent (99%).
|
| g. |
“Accelerated Valuation Period” shall mean the two (2) hour period following the Investor’s written confirmation of the acceptance of the applicable Accelerated Purchase Notice by Investor.
|
| i. |
“Purchase Notice” shall mean a written notice from Company, substantially in the form of Exhibit A attached hereto (a “Rapid Purchase Notice Form”),
Exhibit B attached hereto (a “Jumbo Purchase Notice Form”), or Exhibit E attached hereto (an “Accelerated Purchase Notice Form”) to
the Investor and the Transfer Agent setting forth the Purchase Notice Shares which the Company requires the Investor to purchase pursuant to the terms of this Agreement.
|
| 3. |
Miscellaneous.
|
| (a) |
Except as modified by this Amendment, the Agreement continues in full force and effect in accordance with its terms.
|
|
(b)
|
This Amendment shall be governed by and construed in accordance with the laws of the State of Nevada as set forth in Section 10.1 of the
Agreement and the dispute resolution provisions set forth in the Agreement.
|
|
(c)
|
This Amendment may be executed in any number of counterparts and by electronic transmission (which shall bind the parties hereto), each of
which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
|
|
SILEXION THERAPEUTICS CORP
|
|||
| By: | /s/ Mirit Horenshtein Hadar | ||
| Name: | Mirit Horenshtein Hadar | ||
| Title: | Chief Financial Officer | ||
|
WHITE LION CAPITAL, LLC
|
|||
| By: | /s/ Sam Yaffa | ||
| Name: | Sam Yaffa | ||
| Title: | Managing Partner | ||
|
SILEXION THERAPEUTICS CORP
|
|||
|
By:
|
|||
| Name: | |||
| Title: | |||

|
Tel-Aviv, Israel
|
/s/ Kesselman & Kesselman
|
|
February 12, 2025
|
Certified Public Accountants (Isr.)
|
|
A member firm of PricewaterhouseCoopers International Limited
|
|
Tel-Aviv, Israel
|
/s/ Kesselman & Kesselman
|
|
February 12, 2025
|
Certified Public Accountants (Isr.)
|
|
A member firm of PricewaterhouseCoopers International Limited
|